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ABSTRACT
Effect of Low Energy Argon Laser and
Dihematoporphyrin Ether on the Growth, Viability,
and Catecholamine Production of C-1300 Neuroblastoma
Cells in Tissue Culture
Low power laser induced fluorescence of dihematopor
phyrin ether (DHE, photofrin 2) is used to detect
cancer. The goal was to determine the effect of low
power argon laser light and DHE on C-1300 murine
neuroblastoma cells (MNB, NB41A3). The study groups were
as follows: Control, untreated cells (C), DHE only at
concentrations of 1 (Dl) and 5 (D5) p g/ml , Argon laser
2
light only at exposure times of 1 minute (1.8 J/cm , LI)
2
and 5 minutes (9.0 J/cm , L5), combined treatment of
Light at 1 , 5 minutes, and DHE at 1 , 5 yg/ml.
Nine replicates were performed following incubation
of cells in either 1.0 pg DHE/ml or 5 yg DHE/ml for two
hours. The Cooper Lasersonics lexel model 150 argon
laser was used.
ii
Cell growth was measured by counting cells, and
cell viability by trypan blue exclusion was determined
post treatment at 1, 24, 96, and 144 hours. Catechol
amine analysis of cell supernatant was performed by
Amersham Radioenzymatic Cat-A~Kit assay. The results
were: cell numbers decreased immediately and remained
low for 9 days in the groups treated with Light for 1 and
5 minutes and 5.0 yg DHE/ml, and in Light 5 minutes with
1.0 ug DHE/ml group as compared with all other treatment
groups. Cell viability followed the same trend with the
L5 group, LI at 5 ug DHE/ml, and L5 group at 1 ug DHE/ml
as compared with group C. Cell morphology was altered in
these groups. Cells changed shape becoming rounded,
contained vacuoles, and pyknotic inclusions.
It was concluded that light alone with 5 minutes
exposure kills cells, but light alone with 1 minute expo
sure has no effect on C1300 MNB cells. However, cells
were damaged and killed, affected in groups LJ.D5, L5D1 ,
and L5D5. Catecholamine concentration was below the
detection limit of the assay for most samples. There
fore, no interpretation can be made about using catechola
mines as a marker of cell status.
iii
Low energy argon laser light at the power density
2
of 30 mW/cm and DHE concentrations of 1 and 5 jcg/ml that
is used for detection of cancer causes changes in cell
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INTRODUCTION
Low power, low energy argon laser induced fluores
cence (LIF) of dihematoporphyrin ether (DHE) is used to
detect cancer (1). Photographic methods using filtered
flashes can detect DHE fluorescence in surface lesions
with concentrations of DHE as low as 50 nanograms (2).
Endoscopic detection of cancer inside body cavities
requires the use of laser light.
It is known that high energy laser light and the
photosensitizers DHE or hematoporphyrin derivative (HPD)
kill cancer cells both in vivo (3,4) and in vitro (5,6,7,
8). The in vitro studies involved varying laser energy
densities (joules) and photosensitizer concentrations to
determine maximum killing of cells in monolayers in
tissue culture.
Current techniques of endoscopic detection of
cancer use 10 to 50 milliwatts (mW) per square centimeter
of laser power with the lowest possible tissue concentra
tion of photosensitizer, about 1 to 10 micrograms (u g)
per gram (9).
Laser light alone affects cell metabolism. Low
energy argon laser has cytotoxic effects on Chinese
hamster cells in culture (10). Low energy helium cadmium
laser light has been shown to possess marked anti
inflammatory action (11) and prevents mitosis in mouse
eggs (12). Helium neon laser light affects cell
membranes (13) and growth (14). Effects on cell
metabolism and structure is dependent on the wavelength,
power density, and energy density of laser light.
Research is needed to determine the effect of low power
2 2
(<400 mW/cm ), low energy (<20 Joules/cm ) argon laser on
cancer cells, with and without photosensitizers. Low
energy laser light is defined as that level at which
there is no thermal effect, only photodynamic effect.
Neuroblastoma is the most common extracranial malig
nant solid tumor in children (15,16). It occurs in 500
children yearly in the United States (17). Neuroblastoma
is an extensive, locally invasive cancer (15) found in
the peritoneal cavity and bone marrow. LIF detection and
photodynamic therapy (PDT) are promising new modalities
for identifying and treating neuroblastoma. Makino (3)
has shown that PDT is effective in producing 50% kill in
tumor in highly malignant neuroblastoma xenographs and
C1300 murine neuroblastoma (MNB).
Neuroblastoma is detected and diagnosed by assaying
for elevated levels of catecholamines, specifically dopa
mine, in serum (18), plasma (19), and tissue (20,21).
This specific tumor marker for neuroblastoma may allow
quantitation of tissue-tumor cell destruction when using
cancer killing therapies like PDT or cancer detection
with LIF of DHE.
LIF of DHE may be used in locating neuroblastoma in
vivo, both at the surgical site and in bone marrow. It
is necessary to understand the effect that low energy
argon laser light and photosensitizers may have on
metabolism of neuroblastoma cells before LIF of DHE is
used as a cancer detection method.
In this study, C1300 MNB in tissue culture was used
as a model system to study the effects of low energy
argon laser and the photosensitizer, DHE on cell growth
as an indicator of cell metabolism and reproduction; cell
viability by trypan blue dye exclusion; and explore the
changes in catecholamine metabolism by measuring
catecholamine content of cell medium by the differential
radioenzymatic assay.
The clinical significance of this study is the
possibility of being able to infer the amount of tissue
damage to the tumor and surrounding tissue, predict any
increased proliferation of tumor, and to quantify change
in metabolism of tumor cells by measuring serum catecho
lamine levels following LIF of DHE for detection of
neuroblastoma .
BACKGROUND
Photodynamic Therapy (PDT) and Dihematoporphyrin Ether
(DHE)
"Photodynamic therapy is a new and exciting treat
ment for many forms of localized malignant
disease"
(22). PDT can cause a complete response; that is, kill
all malignant tissue in 60% to 70% of the cases suitable
for this type of treatment (23).
The treatment protocol consists of first injecting
the photosensitizer intravenously. When the photosensi
tizer, dihematoporphyrin ether (DHE), is used in a dosage
of 1-5 mg/kg body weight of the patient, DHE is taken up
by all cells. It is retained longer by the liver,
spleen, skin, intestinal mucosa, and malignant tumor
tissue than it is in other normal body tissues.
After a period of 24 to 48 hours, when normal
tissue contains a lower concentration of DHE than does
malignant tissue, the involved area is irradiated with
light. Most investigators (23,24,25) use red laser light
produced by the argon-dye or gold metal vapor lasers.
2
The suggested power density is from 14 to 400 mW/cm and
the energy density used varies between 25 and 200
2
joules/cm
, depending on the volume and location of the
malignant lesion (23).
Photodynamic therapy is a promising modality for
treating tumors that are resistant to chemotherapy and
ionizing radiation therapy and also for primary local
malignant disease, such as neuroblastoma (58).
Cancer Detection by DHE Fluorescence
Laser induced fluorescence has proven useful as a
diagnostic technique in identifying occult bladder (26)
2
and bronchial tumor as small as 1 mm (27). Endoscopic
detection of malignant disease requires intense laser
light.
DHE fluorescence in surface lesions and tumor
tissue exposed intra-operatively may be detected when
activated with laser irradiation (1) and by filtered
flash photography (2).
Argon (488,514 nm) , krypton (405,413 nm) , nitrogen
(337 nm) , and helium cadmium
(442 nm) laser light is
known to stimulate red (630 nm) fluorescence of
heraato-
6
porphyrin derivative (HPD) and DHE accumulated in tumor
cells in vitro and in vivo (1,5,23,28,29,30,31).
For diagnosis, laser power densities of 10 to 50
2
mW/cm seem to be effective in causing fluorescence
sufficient to identify concentrations of 1 vg DHE/ml in
tissue.
The Photosensitizer - Dihematoporphyrin Ether
Dihematoporphyrin ether is a somewhat purified
component of hematoporphyrin derivative (32). Hemato
porphyrin derivative was first prepared by Lipson (32).
R
Dihematoporphyrin ether is available as Photofrin 2 .
Hematoporphyrin derivative is derived from hemo
globin by treatment with acetic and sulphuric acids to
modify the side chains of the porphyrin
group. There are
seven distinct components to hematoporphyrin derivative
(HPD). The formula for HPD is C34H386N4' Molecular
weight is 588.7. It is excited at 405 to 630 nm. The
wavelength maximum is 405 nm. It fluoresces between 600
and 700 nm. The fluorescence maximum is 630, with a
second maximum at 690 nm. It forms aggregates in aqueous
solution. It is lypophillic. Its uptake and retention,
cancer cells to normal cells, is 10:1. Standard dose is
1 to 5 mg of HPD/kg bodyweight. Its retention time is 24
to 72 hours. A side effect of this treatment is
photosensitivity, especially of skin and eyes. Elimina
tion pathway is the liver and the gastrointestinal tract.
Dihematoporphyrin ether, the so called active component
of HPD, has a molecular weight of approximately 627
(32). The structure appears in Figure 1. The absorption
emission spectrum (Figure 2) of DHE is similar to HPD.
Photosensitization is a photodynamic action
involving light, oxygen, and the photochemical, DHE.
There are two types of reactions. Type 1 reaction is a
direct photosensitizer interaction which produces proton
or electron donors. In the Type 2 reaction, the photo
sensitizer transfers excitation energy to the oxygen
ground state forming singlet oxygen (33,34).
Fluorescence occurs when light activated DHE sing
let state is formed and decays to the ground state. The
DHE singlet state can decay to the triplet state to
release light as phosphorescence or react with oxygen to
form singlet oxygen (33). The reactive singlet oxygen
tears apart proteins, oxidizes lipids in biological mem
branes (31), and interferes with cytochrome c oxidase in
the mitochondria (35).
8
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Figure 1. Structure of HPD-active component.
Dougherty, Potter, Weishaupt (32)




FIGURE 2. Absorption Emission spectrum of DHE.
Absorption 590-730nm, Emission
- 630nm.
Obtained on Perkin Elmer LS-5
spectro-
fluorimeter. 50 ug DHE dissolved in 95%
Ethanol .
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Serum proteins are responsible for porphyrin
transport in the bloodstream and the endocellular
concentration of hematoporphyrin (Hp) and related
porphyrins (36). A higher concentration of DHE/HPD is
needed to photosensitize cells in tissue culture if the
medium contains serum.
Uptake rate and cellular deposition of DHE and HPD
in tumor cells in vivo and in vitro have been
characterized by many investigators (26,29,31,37,38).
Most cell lines take up DHE in 1 to 24 hours at doses
ranging from 1 to 25 uS/ml (37). Berns (37) has shown
uptake into cytoplasm and nuclear membranes peaked at 24
hours with concentrations of 25 pg/ml. Berns (37)
achieved similar photodynamic kill of Chinese hamster
ovary cells incubated for one hour with 25 ug HPD/ml plus
1% serum and when incubated for 12 hours with 25 ug
2
HPD/ml plus 5% serum. Power levels were 5-100 mW/cm of
either argon dye (630 nm) or gold vapor laser (628 nm) .
DHE binds nonspecif ically to serum protein.
Increased cytotoxic effect of DHE occurs with shorter
incubation time, if serum is omitted from tissue culture
medium (39). This information helped determine the
incubation time of cells with DHE in the experimental
design of the work reported here.
11
Today, experimental studies in humans, animal, and
cell culture tumor models (38) are underway with DHE and
with other photosensitizers such as Cryptocyanines, Nile
Blue A, Dequalinium, Chloroaluminum phthalocyanine tetra-
sulfate, chlorins and purpurins.
Photobiology and Photochemistry
Phototherapy is a common clinical modality. Some
uses are: 1) to increase pigmentation by increasing
melanin production and numbers of melanocytes; 2) to
reduce tissue bilirubin concentration by using blue (454
nm) light; and 3) to alter Cortisol levels, thus
circadian rhythm, by controlling light exposure via the
day-night cycle.
Laser technology has stimulated basic and clinical
research in PDT, biostimulation, and biosuppression.
Laser-induced fluorescent detection of DHE in malignant
tissue involves the use of low energy laser light. Each
wavelength or color of light has specific absorption
energy levels, and this determines the selective
absorption by the different photochemicals.
12
Photodynamic therapy (PDT) of cancer cells in
culture had been performed by various investigators.
Most PDT involves the use of 630 nm light at laser powers
of 100 milliwatts (mW) to 1 watt (W) and energy densities
of 100 to 300
J/cm2
(28). Light transmission through
tissue is maximized at red (630 nm) wavelengths.
Anderson has shown that violet laser light (405 nm)
is more effective at killing cells in culture at low
power densities (i.e., 20-40 mW/cm2) and low doses of HPD
(1-25 ug/ml HPD) than red light. Violet light causes
quicker kill than 630 nm red light (30), because DHE
absorbs light more efficiently at 400-520 nm.
Low energy and low power laser light has been shown
to stimulate and/or inhibit cell growth (41,42,43). Low
light inhibits causes changes in light sensitive amino
acids and proteins. Argon (514 nm) laser light alone at
2
energy densities of 100 to 400 J/cm has cytostatic and
cytotoxic effects (42).
Mester (43) reviewed laser light effects on 15
2
biological systems and reported that low energy 1 J/cm
of ruby laser light stimulated phagocytosis in leukocytes
and increased mitotic index in Erhlich acites tumors but
13
2
2 to 4 J/cm inhibited leukocytic phago-cytosis. He used
HeNe (50 mW, 630 nm) and Argon (100 mW, 400 nm) at energy
2
density of 4 J/cm , two times a week on the total wound
surface and this speeded healing of ulcers. Kubasova
(13) showed that 1 J/cm of the HeNe laser light applied
once every 24 hours for four days changed the surfaces
of exposed cells. Cells showed pits. This information
is important in support regarding changes in cellular
morphology and growth characteristics of low energy argon
laser light radiation (488, 514 nm) without DHE in the
cells.
Neuroblastoma
Neuroblastoma is a hormone and amine secreting
tumor derived from sympatheticoblast melanocytes and,
therefore, from embryonic neural crest cells (44). Neuro
blastoma and pheochromocytomas share with neural tissue
the capacity to synthesize and release biogenic amines:
histamine, 5-hydroxytryptamine (serotonin, 5-HT), dopa




droxyphenylethylamine) and the breakdown product of
dopamine, homovanillic acid (HVA) , are indicators of
neuroblastoma (18) and, rarely, of pheochromocytoma (45).
14
Various methods are used to measure catecholamines for
the diagnosis of neuroblastoma.
Reynolds reported the use of catecholamine
fluorescence and morphology of cells isolated from human
tissue and grown in tissue culture to differentiate
neuroblastoma from ganglioneuroma and pheochromocytoma
(46). Proye reported that pheochromocytomas do secrete
dopamine (47). Techniques of catecholamine fluorescent
staining and observation of the morphology of cells grown
in tissue culture are more specific for diagnosing neuro
blastoma than is measurement of urinary VMA and
catecholamine (46). Helson used a formaldehyde induced
fluorescent method for the detection of intracellular
catecholamines in neuroblastoma cells in human bone
marrow aspirates and cultured cells from human and murine
sources (C1300 tumor) (48).
C1300 Murine Neuroblastoma (MNB) has been identi
fied as a model of human disease (45,50,51,52). These
cells contain and secrete catecholamines (45,46,49,51).
Pons (51) reported levels of catecholamines from biologi
cal specimens from control and C1300 MNB tumor implanted
animals. Catecholamines were assayed by using HPLC and
an electrochemical detector. In primary tumors, dopamine
and norepinephrine were detected, but there was no




Tumor X value (ng/g) Serum (ng/ml)
n=10 Control Tumor
DA 28 + 14 0.4 + 0.4 21 + 2.3
NE 207 + 40 19.3 + 5.1 39 + 7.7
E ND 23.2 + 13.9 12.8 + 4.7
These levels are 1,000 times greater than is expected in
monolayer cell cultures.
Catecholamine levels in plasma decrease following
surgical excision of tumor and may increase with
recurrence (53). Plasma and 24-hour urinary estimates
are the best sample choices since plasma levels may be
elevated in the absence of free urinary catecholamines;
tumors excrete catecholamines inconsistently and urinary
excretion follows a diurnal pattern (53).
Catecholamines
The catecholamine neurotransmitters are
noradren-
alin, adrenalin, and dopamine (3
ethylamine). Catecholamines are synthesized from
L-
tyrosine through a series of enzymatic reactions that
16
form dopamine, noradrenalin, and adrenalin. In the parts
of the nervous system that release dopamine as a neuro
transmitter, no further metabolism occurs and dopamine is
stored in vesicles in the presomatic nerve terminal.
Cat-
abolism of catecholamines occurs by amine degradation by
the enzyme amine oxidase. Catecholmethyltransferase and
aldehydedehydrogenase degradation occurs in all tissues
including nerves, liver, intestine, and kidney. Figure 3
shows the synthetic and degredation pathways of
catecholamines .
Biosynthesis of catecholamines is rate limited by
the level and activity of tyrosine hydroxylase (56).
This enzyme is oxygen dependent and kinetic properties
suggest oxygen availability may limit synthesis of
catecholamines (55). Tyrosine hydroxylase is inhibited
by dopamine and norepinephrine (54).
Dopamine is converted to norepinephrine by the
action of dopamine-B-hydroxylase. This is a mixed
function oxidase requiring oxygen and a cosubstrate.
Dopamine-B-hydroxylase is found in granules which store
epinephrine and has been used as a marker for the

















































































FIGURE 3. Synthetic and degradation pathways of
catecholamines (18).
18
The state of the art alternative for determination
of catecholamine is high performance liquid chroma
tography (HPLC) with electrochemical detection (57). See
appendix Coulochem Application Note.
Method of Catecholamine Analysis
Catecholamine analysis was performed with the Cat-A-
R
Kit (Amersham). This radioenzymatic assay makes use of
the enzyme catechol-o-methy-transf erase to catalyze the
3
transfer of H-methyl group from
S-adenosyl-L-methionine-
3 3
( H-methyl)( H-SAM) to norepinephrine, epinephrine, and
dopamine. The resulting products are extracted by thin
layer chromatography. Isolated derivatives,
metane-
phrine, and normetanephrine are converted by periodate
3




is not susceptible to periodate
oxidation. This chemical step serves to differentiate
dopamine from the other two catecholamines. The
commercial protocol appears in the Appendix.
Preliminary Investigations
Preliminary studies were performed to establish
quantitative techniques for measuring cell number, viabil
ity, catecholamine values, and for documenting changes in
cellular morphology.
19
To control the effect of environmental conditions
of the cell culture, pilot experiments were performed to
determine the effect of room lights on cells with varying
concentrations of the photosensitizer DHE.
Levels of DHE were then chosen to give varying
amounts of cytotoxic effect so that cell growth and
morphology could be studied.
Finally, since DHE is lipophillic and hydrophobic
and sticks together in aqueous solution, it was important
to determine that DHE concentration was correct upon
dilution. To verify the concentration of DHE, the
absorbance of three diluted samples was measured. The
concentration was calculated from Beer's law.
Catecholamines
Catecholamine levels were determined in intact
cells by fluorescent staining (Appendix), in homogenized
cells, and in the medium supernatant. Catecholamine
staining was positive in intact C1300 MNB (4B41A3)
cells. In cells, quantitative values of catecholamines
R






Norepinephrine (NE)(pg/ml) 41-303 241
0-33 303
not detectable




Mouse plasma was assayed for catecholamines
















The catecholamine levels show that this tumor line pro
duces dopamine in vivo. All catecholamine levels were
R
determined using the Amersham Cat-A-Kit assay at a
reference laboratory.
This initial evidence led me to believe there would
be enough catecholamine present in medium to measure
variation of catecholamine levels following treatment
with laser light and DHE.
Characterization of Growth and DHE Toxicity on C1300 MNB
Cells - Clone NB41A3
Normal growth curves were defined for C1300 MNB
cells in 48 well plates with no change of medium for 10
days. Cell morphology was observed every day for 10 days.
Cells become more spindle shaped and display neurite-like
structures on day 3 to day 7. Thus, the earliest day
chosen to treat cells with drug and light was day 3,
since neurite-like structures are related to the presence
of catecholamines.
To determine the DHE toxicity with and without room
lights on, cells were grown in 48 well plates and exposed
to photosensitizer for two hours. Cells were not washed,
22
but medium with DHE contained no serum. Results appear
in Figures 4 and 5. Toxicity of drug and light were
performed with 10 to 50 argon laser light and 0.5
to 25 ug DHE/ml with a two-hour incubation time.
Results
2
10 mW/cm argon laser and DHE levels of up to
5 ug/ml do not cause cell kill or gross changes in cell
o
morphology. Light levels of >30 mW/cm with DHE levels
MO ug/ml kill all cells present. Therefore, drug levels
2
of 1 and 5 ug DHE/ml and light levels of 30 mW/cm were
used to determine sublethal effects on cells in culture.
There is a slight decrease in cell numbers for the
concentrations of 5 and 10 ug DHE/ml from day 4 to day 7,
as compared to control cells incubated without DHE. The
effect of room lights on cell growth is noticeable.
Because of this, the studies on the effects of
laser light and DHE on C1300 MNB cells were performed in
_2
the dark (1.4 lumens ra ), with room lights off and the
hood light off.
23
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FIGURE 4. Growth curves of C1300 MNB (4B41A3) with
different concentrations of DHE and room
lights on.
24








i i r~r i i ? J r 10
DAVS
FIGURE 5. Growth curves of C1300 MNB (4B41A3) with
different concentrations of DHE in the
dark.
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Results of Confirming Accuracy of Dilution of DHE
DHE is lipophillic and hydrophobic and may stick
together, leading to inaccurate dilutions. Using Beer's
law, the concentration of DHE in solution can be
determined by measuring the absorbance.
Beers 's Law:
A = abc
where A = absorbance, a
=
molar absorptivity
coefficient (or E, extinction coefficient),
b = 1 cm path length of sample cell, and
c
=
concentration in moles or grams.
Physical and chemical constants for HPD and DHE
are:
DHE a = 5000 @ 506 nm
HPD E = 0.126 @ 405 nm
DHE molecular weight = 627
Reorganizing Beer's law equation for concentration:
c
= A/ab
Using this equation and physical chemistry data
given, the concentration of each DHE dilution can be




The results are tabulated below and shown graph
ically in Figure 6. These results show that DHE is
soluble in medium. When diluted, the measured
concentrations match the calculated values. Measuring
the absorbance at the 405 nm wavelength gives values
closer to the calculated values than when measured at the
506 nm wavelength. If the linear results at 405 nm were
correct, DHE absorbs light like HPD. If the linear
results at 506 nm were correct, then DHE does aggregate.
I assumed absorptivity at 405 nm was correct because DHE
has 20% HPD.
The Experiment - An Overview
The purpose of the experiment is to determine the
effect of argon laser and the photosensitizer DHE and a
combination of both, on C1300 MNB cells. C1300 MNB cells
isolated from fresh tumor removed from mice were grown in
tissue culture flasks for three to four days and passed
in tissue culture. Cells were plated at a concentration
4
6 x 10 cells per milliliter into 48 well tissue culture
trays. Cells were grown 72 hours in Ham's F10 medium
with glutamine, 2.5% Fetal Bovine Serum, and 15% Horse
serum. At 72 hours, cells were washed once with
27
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DILUTION CURVE OF DHE IN HAM'S MEDIUM
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FIGURE 6. Dilution curve of DHE in Ham's F10
medium.
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magnesium and calcium free Phosphate Buffered Saline
(PBS) to remove serum. Ham's F10, without serum, with or
without DHE, was added to the appropriate treatment or
control well for a two hour, 37C incubation. Following
the two hour incubation, cells were washed once with
calcium and magnesium free PBS to remove residual DHE.
Fresh growth medium with supplements was added to
_2
all wells. The plates were treated with 30 mW cm
^
argon
laser light or left in the dark. One hour post
irradiation, cells were sampled for cell number,
viability, and supernatant medium saved for catecholamine
analysis. Wells in each group were sampled on days 3,
pre and post treatment, 4, 7, and 9. Photographs were





Mouse neuroblastoma C1300 MNB - NB41A3 (ATCC-CCL-
147) was obtained from American Tumor Cell Collection.
Tumor was implanted subdermally in A/J male (Jackson
Laboratories, Bar Harbor, ME) mice six to eight weeks
old. After 14 to 21 days, following sacrifice of the
animals by cervical dislocation, tumors were excised.
Prior to excision of the tumor, dead rats were dipped
into alcohol and then skin over the tumor was shaved. The
tumor was removed and trimmed of necrotic and non-tumor
tissue. The tumor was strained through a sterile stain
less steel mesh screen into a sterile petri dish
containing Ham's F10 medium (Flow Laboratories, McLean,
VA) with 2.5% Fetal Bovine Serum, 15% Horse Serum, 6 u M
glutamine, and 100 units per milliliter of penicillin and
streptomycin (Flow Laboratories, McLean, VA). Cells were
plated into T-25 Falcon culture flasks (Fisher Scien
tific, Rochester, NY) and passaged routinely at 1:3 ratio
twice a week to ensure viability and exponential growth.
Cell cultures were maintained at 37 C in a humified
atmosphere of 95% air and 5% C02 .
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DHE - The Photosensitizer
Dihematoporphyrin ether (DHE, Photofrin 2R) was
obtained from Photofrin Medical, Inc. (Raritan, NJ).
Four vials of DHE (Lot 249C) were stored at -80C. Each
vial contained 30 ml of DHE at a concentration of 2.5
mg/ml. Prior to use, a vial was thawed and 4 ml portions
were pipeted into 17 x 100 mm sterile polypropylene test
tubes with caps (Fisherbrand, Fisher Scientific, Roches
ter, NY). Aliquots were stored at -80C until use. Lot
249C of DHE was used for the entire experiment.
Serial dilutions of 1.0 and 5.0 ug DHE per milli
liter in Ham's F10 medium without serum were made from
freshly thawed DHE stock (2.5 mg/ml). Dilution-concentra
tion curves were determined by measuring absorbance and
calculating actual concentration from Beer's law.
Preliminary studies have shown DHE has an extinction
coefficient the same as hematoporphyrin derivative
(photofrin 1), which is 0.126 cm u g
DHE stock and working solutions were kept in the
dark. One milliliter of Ham's F10 medium containing
DHE was added to the appropriate treatment well two
hours prior to irradiation with laser light.
32
Argon Laser and DHE Effects on Morphology, Growth, and
Viability
Cells growing exponentially in three to four day
old culture flasks were displaced by multiple washing
with fresh medium. Cell numbers (cells/ml) in the stock
culture were determined by counting on a Coulter Counter
Model ZF (Coulter Electronics, Inc., Hialeah, FL). The
stock solution of cells was diluted with medium to 6 x
4
10 cells per milliliter. Actual cell number was
determined by automatic counting before plating. One
4
milliliter of 6 x 10 cells was added to each of 18 wells
of a 48 well tissue culture cluster plate (Costar,
Cambridge, MA). Two 48 well plates were set up per
replicate. Cells were grown for three days prior to
treatment. At three to seven days, the cells were round
and spindle shaped with neurites.
Observation of cell morphology, cell counts, and
viability assessment were performed on replicates on days





Morphology of cells in each well at each time
interval was assessed with the aid of a Nikon inverted
phase microscope at 200x magnification. Photographic
records were made with an Olympus OM-1 35 mm camera
attached to the microscope via a Nikon extender tube.
Kodak 200 ASA color slide film was used. A photograph
was taken of cells in each well. Then cell counts were
made of the attached cells. Cell medium was removed and
saved for catecholamine analysis or for viability
studies.
Cell Counting
Cells were detached from the surface of each well
of the 48 well plate by incubating them for 10 minutes in
0.2 milliliters of trypsin-EDTA (Flow Laboratories,
McLean, VA) at room temperature. After 10 minutes, 0.3
milliliters of calcium and magnesium free phosphate
buffered saline (PBS) was added to each well to stop
trypsination and to bring the volume to 0.5 milliliter.
Cells and trypsin-PBS solution were removed from
wells by scraping the well bottom with a
disposable pipet
tip that was attached to a 1000 1
Socorrex variable
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pipet (VWR, San Francisco, CA). This pipet was used to
transfer well contents to culture tubes by first
reflux-
ing medium five times to free and mix cells. Cells were
removed from wells and placed into 12 x 75 mm round
bottom non-sterile polypropylene culture tubes (VWR, San
Francisco, CA).
Cell counts were performed on the Coulter counter
following a 1:100 dilution (200 u 1/20 ml) using a Coulter
diluter II (Coulter Electronics, Inc., Hialeah, FL).
Diluent with cells was dispensed into 30 ml sample
vials. Sample vial was placed on the counter and 0.5 ml
was aspirated. The readout displayed the absolute count
of cell numbers. This number was multiplied by 200 to
get cell number per milliliter.
Cell Viability
Cell viability was determined by trypan blue
exclusion. Following sampling for cell counting, the
remaining cell solution in the
12 x 75 mm culture tube
was used for viability studies. One drop of filtered
0.16% Trypan Blue was added to the culture tube with a
disposable pasteur pipet.
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The sample was mixed briefly on a maxi mix 1
multitube vortex mixer (Therraolyne, Dubuque, IA). One
drop of each sample was placed onto a glass microscope
slide inside a 1 cm diameter ink circle. The ink circle
retains the drop. Cells were allowed to settle for three
to five minutes. One photomicrograph each was taken of
two fields of cells in each ink circle. The microscope
camera set-up was used, as described for
photodocumentation of cell morphology. Live and dead
(blue) cells were counted, from the projected color
slides to determine cell viability of each well. Cell
viability was reported as percentage live to total cell
number.
Treatment
The cells were treated on the third day after
having been plated into 18 wells, 4 wells at each corner
and 2 central wells, of two 48 well plates. Immediately
prior to treatment, medium was removed from all wells
with a sterile pasteur pipet attached via tubing to a
suction flask. Cells in all wells were washed with one
milliliter of 37C PBS with calcium and magnesium to
remove serum. PBS was removed with a pasteur pipet and
suction.
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One milliliter of Ham's F10 medium with glutamine
without serum was added to both the control and the
"light
only"
treatment wells. The room lights and hood
lights were turned off. Light levels were measured with
a Gossen luna pro light meter (West Germany). Light
_2




with the room lights off. One milliliter of
Ham's F10 with glutamine without serum and with either







Plates were incubated for two hours in total dark
at 37C in a humidified 95% air and 5% C02 environment.
Immediately following the two-hour incubation, photomicro
graphs were taken of one well in each group for
documentation of cell morphology.
All wells were washed with 1 ml, 37C PBS with
calcium and magnesium. Then one milliliter of Ham's F10
medium with serum was added to each well.
Plates with control and DHE only wells were placed
in the tissue culture hood in the dark at room
temperature. Plates with light only control wells and
37
PDT wells were irradiated via a 600 pm glass fiber
(Cooper Lasersonics, Santa Clara, CA) with 30
argon laser (Lexel Model 550, Cooper Lasersonics, Santa
Clara, CA) light for one minute (1.8 Joules/cm2) and five
minutes (9.0 Joules/cm ) in a darkened room at room
temperature. Immediately following treatment, photomicro
graphs were taken of one well in each group to document
cell morphology. All plates were returned to the 37C,
5% CO incubator for one hour.
After one hour, the medium was removed from one
well in each group and it was saved for catecholamine
analysis. The trypsin was added to one well in each
group to release cells from the plate surface, followed
by cell counts and trypan blue viability determinations.
The plates were returned to the 37C incubator for six
days. All photomicrographs, cell counts, trypan blue
viability determinations, and cell washings were
performed in the darkened room.
In pilot studies, temperature of the medium was
measured during the time of irradiation with the argon
laser. No temperature change occurred.
38
Experiments were run in duplicate for "control" and
"DHE only" groups and one repetition for each light only
group
- 1 and 5 minutes, and each light and DHE combina
tion (PDT). Fourteen replicates of each experiment were
performed.
Laser Dosimetry and Beam Profiling
The argon ion laser outputs light at 488 nm and 514
nm. Power output of the argon laser from the fiber tip
was measured with the Liconix PM45 power meter (Liconix,
Sunnyvale, CA). This power meter has a photoreceptor
cell calibrated to each of four wavelengths. The power
meter was set at a range of 30 mW, 514 nm wavelength.
2
The photoreceptor cell has an aperture size of 0.38 cm .
2
Therefore, to determine power in milliwatts per cm , the
meter reading is multiplied by 2.63. The irradiation
took place in an air regulated incubator. The fiber was
placed 25 centimeters below the plate holder so that a
spot or beam diameter of 7.0 cm was obtained. Beam
sighting was enhanced by reflecting the beam off a card
coated with fluorescein. The diameter was measured
across the homogeneous beam cross section.
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Power measurements were made at the center point
and at each quadrant, 1 cm from center, and 3.5 to 4 cm
from center. In the 1.5 cm diameter circle that covered
the four simultaneously treated wells, the power level





all irradiations. Four corner wells were irradiated at
once within the 1.5 cm diameter circle. For one minute
of argon exposure, the energy density is 1.8 Joules
and for five minutes is 9.0 Joules cm .
Catecholamine Analysis
Samples of growth medium were obtained from wells
containing C1300 MNB cells at each time interval and from
all groups prior to cell counting. One milliliter of
medium was removed from each well using a sterile
five-
milliliter serological pipet (Fisher Brand, Fisher
Scientific, Rochester, NY) and transferred to an ice cold
four-milliliter blood collection tube (Amersham,
Arlington Heights, IL) containing EGTA (ethylene
glycol-
bis (B-aminoethyl ether) N,N -tetra acetic acid) and
reduced glutathione. Immediately thereafter, the tubes
were centrifuged for 10 minutes at 800 g. Then cell-free
medium was decanted into 17 x 75 millimeter clear polysty
rene test tubes (Falcon 2054, Fisher Scientific, Roches
ter, NY) capped and immediately frozen to -80 C.
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The differential catecholamine determination was




, Amersham). Medium from one replicated each,
using 1 ug DHE/ml and 5 ug DHE/ml as treatment
concentrations, was sampled for dopamine, epinephrine,
and norepinephrine. Samples were thawed immediately
prior to analysis and kept on ice. Samples were run in
quadruplicate with two tubes for sample alone and two
tubes with samples spiked with 100 pg/ml of dopamine,
epinephrine, and norepinephrine. The complete step by
step protocol and materials list appears in the appendix.
Application Notes
The samples were reacted with the enzyme isotope
mixture for one hour in a shaking water bath. After this
reaction and all extractions, sample catecholamines in
acetic acid were frozen to -80C until the next day.
Thin layer chromatography was performed. Separation took
60-90 minutes for four plates in a glass developing tank.
The tank had saturation pads and a solvent volume of 88
milliliters.
Prior to counting on a Beta counter, all vials were
shaken for 45 seconds and dark adapted at least two
hours .
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Vials were counted on a refrigerated Packard 460C
(Downers Grove, IL) liquid scintillation counter.
Results were reported in picograms of catechola
mine per milliliter (pg/ml). Concentration of each cate
cholamine was determined by the following formula:
+
Standard
Concentration = CPM sample - CPM Blank x 100 pg/ml
(pg/ml) CPM standard
- CPM Sample 0.050 ml
*
CPM = counts per minute
42
STATISTICAL ANALYSIS
Distribution and comparative statistics ANOVA,
the Student's t-test and graphical display of variance
were used to define and compare cell count and viability
data within and between treatment groups.
All statistical computations were performed using
p
Statpro (Penton Software, NY, NY) software.
Quality Control
Cell counting precision and accuracy determined by
measuring the level of 14.7 um microspheres (Coulter
Electronics, Hialeah, FL) in solution. Microsphere
counts were determined every Monday. The mean
coefficient of variation of triplicate cell counts was
reported.
Catecholamine precision and accuracy was determined
by measuring the level of dopamine, epinephrine, and nor





The appearance of cells in the tissue culture well
at various times pre and post treatment gives a qualita
tive picture of cell status. Photomicrographs from an
experimental replicate, using DHE 5 ug/ml, show character
istics of shape, size, density, and cellular inclusions.
These photomicrographs are representative of the cell
morphology of all experimental replicates. These are
photomicrographs of the "control
groups"
pre and post
treatment and of the "worst
case"
treatment groups.
Cells were harvested from stock cultures and
4
diluted to 6 x 10 cells per milliliter. One milliliter
was added to a well that has a surface area of 1 square
centimeter.
Characteristic morphology of untreated cells, 48
and 72 hours after plating, appear in Figures 7A and 7B.
At day 2 (Figure 7A), cells attached to the plate have



























































like structures began to appear on spindle cells. At day
3 (Figure 7B), more cells are evident and cells are
assuming the characteristic shape of nerve cells, with
long dendritic structures. The cytoplasm is clear.
Cell morphology changes with time and after treat
ment. All wells, thus all cells, were washed once prior
to treatment with photosensitizer to remove serum
proteins from cells. The cells were washed a second time
following the two-hour incubation with DHE and without
DHE. This wash was to remove residual DHE from cells.
Photomicrographs were taken of cell morphology of
"control"
nontreated, light only, and DHE only groups
and of treated light and DHE at times immediately (Day
3) after, and at 1 hour (Day 3), 24 hours (Day 4), 96
hours (Day 7), and 144 hours (Day 9) post irradiation
with the argon laser. All photomicrographs were taken at
200x magnification unless noted otherwise.
Figures 8A-F show the changes in cell morphology
for the control, DHE only-5 ug/ml, light
only-1 minute,
light only-5 minutes, light-1 minute and DHE-5 ug/ml, and
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groups, A-D, cell washing has
reduced the number of cells. The cells were less spindle
shaped because of being less attached. Dark granules
were seen in a few cells in Figure 8B, DHE only control.
Light only at both 1 and 5 minutes increased the number
of vacuoles in the cells. Overall, all cells in these
groups appear normal.
The morphology of cells in the light and DHE-5 pg/
ml treatment groups immediately following irradiation
detached from the cell surface and become rounded. Cells
appear pyknotic granular with dense and frequent
inclusions. Laser light and DHE treated cells were
injured or killed, causing the observed effects on cell
morphology.
There was no difference of cell morphology between
groups treated with 1 minute and 5 minutes of laser light
at the DHE 5 vg/ml level and light-5 minutes and DHE
1 rig/ml level. Morphology of cells treated with 1 minute
argon laser light and DHE 1 ug/ml was no different than
light-1 minute alone.
After treatment, cells were incubated at 37 C in a
5% C0Q environment. At one hour
post treatment, cell
50
morphology appears the same as immediately after
treatment, except in the light only-5 minutes and treated
groups. In the light only-5 minutes group, cells are
rounded and small appearing to be injured or dead. In
the "light-1 minute and DHE 5 u
g/ml"
group, cells are




groups (Figures 10A-D) , at 24
hours post treatment, cells had increased in number and
started to show characteristic spindle shape. Some cells
started to form neurite-like structures. Cell morphology
in the light only-5 minutes group showed dense cell
numbers the same as in the untreated, DHE only, and light
only-1 minute groups. In the light and DHE treated
groups (Figures 10E-F), cells that were injured were
still rounded and dead cells were disintegrating. A few
cells started to recover but still were pyknotic.
Cell morphology appears in Figure
11A-C at 96 hours
(day 7) and Figures 12A-C at
144 hours (day 9) post
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FIGURE 11C. Cell morphology Light 5 minutes and



















































































FIGURE 12C. Cell morphology Light 5 minutes and
DHE 5 Pg/ml 144 hours post treatment
Day 9.
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Cells that survived the treatment were observed in
the light and DHE treated groups (Figures 11B-C and 12B-
C). Most were rounded with unpaired cell function. A few
recovered to show normal cell morphology.
Cell Growth
Living cells reproduce exponentially in tissue
culture wells. Cell counting at selected time intervals
gave a quantitative measure of growth. Cell counts were
performed on cells from all wells of each replicate.
Results are compiled in Table 5. These results are
represented graphically in Figure 13.
Experimental Design
Each experimental replicate ran over nine days.
Each replicate had two untreated control four-well
clusters, two DHE only four-well clusters, and one
four-
well cluster for light-1 minute, light-5 minutes, and one
cluster each for the light and DHE treated groups. The
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FIGURE 13. Growth curves of pre and post treated
groups. C=control, D1=DHE only lug/
ml, D5=5 ug/ml, Ll=Light only 1 minute,
L5=Light only 5 minutes, LlDl=Light 1
minute and DHE 1 ug/ml, LlD5=Light 1
minute and DHE 5 ug/ml, L5Dl=Light 5
minutes and DHE 1 ug/ml, L5D5=Light
5 minutes and DHE 5 ug/ml. Day 3.5 is
equivalent to 1 hour post irradiation.
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Quality Control - Cell Counting
To ensure accurate and precise cell counts,
statistics were monitored; counts of a standard solution
of 14.7 um latex microspheres, the intra-assay variation
of the triplicates, and the level of background counts.
Every Monday during the experiment, the microsphere
solution was counted following dilution (1:200). The
mean cell count was 5912 (n=10). The intra-assay
variation of triplicates was 1.7% (1 CV). The inter-
assay or weekly variation was 5.6% (1 CV). The mean
intra-assay variation for all cell counts was 2.1% (1
CV).
The background count was measured daily by counting
0.9% saline dilution fluid. The mean background count
was 30.3 + 48% (1 CV) .
Experimental Results
Cells were plated into wells of a 48 well plate on
4
day 0 at a concentration of 6 x 10 cells/ml. At day 2,
5
mean cell count was 3.1 x 10 cells/ml and continued to
5
increase to a day 3 pre-treatment level of 4.9 x 10
cells/ml .
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At one hour following treatment, after two washes,
in the DHE only and treatment groups, and two-hour incuba
tion with DHE and the argon laser light treated groups,
5
cell counts dropped to values between 2.8 x 10 and 3.2 x
5
10 cells/ml. The decrease of cell numbers in the
"control"
groups was from washing. Additional loss of
attached cells was seen in DHE 5 ug/ml and light treated
groups, and in the DHE 1 ug/ml and light-5 minutes
5
group. Cell counts dropped to a level of 1.2 x 10
cells.
At 24 hours after treatment, Day 4, the control,
DHE only, and light only groups increased to between
5 5
5.5 x 10 and 6.4 x 10 cells/ml and continued to
increase slightly until day 9.
The cells treated with DHE-1 u g/ml and light
exposure of either one or five minutes recovered at
slower rates. At 24 hours post treatment, the light-1
5
minute, DHE 1 ug/ml cells grew to 3.4 x 10 cells/ml,
whereas the remaining treated cell groups remained at 1.6
5
- 1.9 x 10 cells/ml.
At 96 hours (Day 7) and 144 hours (Day 9), the
cells treated with light and DHE-1 ug/ml continued to
66
increase in cell number. The group treated with light
for one minute and DHE-5 ug/ml showed a slight increase.
The cells treated with light for five minutes and DHE-
5 ug/ml leveled and then decreased in cell number over
the remaining six-day period.
Statistical Comparisons of Differences
The null hypothesis for this experimental design is
that the mean cell counts are equal for each group at
each sampling time. To test this hypothesis, variance
plots were produced from the distribution statistics and
test statistics were calculated by analysis of variance
(ANOVA) and the Student's t-test.
Variance plots were created and appear in Figures
14A-D, corresponding to one hour (Day 3), 24 hours (Day
4), 96 hours (Day 7), and 144 hours (Day 9) post
irradiation.
The variance plots show the mean (X) , +1 and 2
standard errors (horizontal bars), +1 and 2 standard
deviations (shaded box bars), and the range (vertical
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FIGURE 14A. Variance plots of mean cell numbers at
1 hour post irrdiation.
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DAY 4





























FIGURE 14B. Variance plots of mean cell numbers at



















































































FIGURE 14D. Variance plots of mean cell
numbers at
144 hours post irradiation.
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These plots allow the visualization of the variance
and allow inference of sameness or difference of the
means. ANOVA and the t-test give quantitative values of
probability of sameness or differences. The results are:
On Day 3 (Figure 14A) , at one hour post irradia
tion, there is no difference (the null cannot be
rejected) in the mean cell number of any group except
that of the light-5 minutes and DHE-5 ug/ml treated
group. The cell number is significantly (p < 0.0005)
lower than that of all other groups.
Over time, effects of disrupted structure and
biochemistry increase. At 24 hours (Day 4), cell numbers
decreased in the post irradiation (Figure 14B). Cell
numbers decreased in the light and DHE treated groups.
There is no difference in the mean cell numbers of the
untreated-control, DHE only, and light only groups.
There is no difference in the mean cell numbers of
the light and DHE treated groups at light exposures of
five minutes and DHE concentrations of 1 and 5 ug/ml.
There is a significant difference (p < 0.005) of the mean
cell numbers of these and of the
"control"
groups. Light
and DHE at these levels cause cells to detach, which
indicates cell death.
72
The light-1 minute and DHE-1 ug/ml treated cells
have a mean cell count that is significantly different
(p < 0.02) from all other treatment groups. At 96 hours
(Day 7) post irradiation (Figure 14C), there is no
difference in the mean cell numbers of the "control"
groups and light-1 minute, DHE 1 ug/ml group (L1D1).
There is no difference in the mean cell number of any of
the remaining treatment groups.
There is a significant difference (p < 0.036)





and the other treatment groups.
At 144 hours (Day 9) post irradiation (Figure 14D) ,
only the light-5 minutes and DHE 5 ug/ml group has
significantly (p < 0.0002) lower mean cell count, as
compared with the other groups.
Cell Viability
Trypan blue dye exclusion test was performed to
determine the number of dead cells attached and of all
cells attached and detached in the sample wells. Live
cells exclude the dye. The percent viability was calcu
lated by subtracting the number dead from the total
number of cells counted and then multiplying the result
by 100.
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Photomicrographs of cells in two separate fields
were recorded. Cell counts of live and dead cells were
recorded. Total number and the number of living cells
was calculated. The count of two fields was averaged.
Representative photomicrographs of live and dead
(blue) cells at one hour post irradiation appeard in
Figures 15A-F. In this underexposed photograph (Figure
15A), control cells were unstained, corresponding to 90+%
viability. The same was true for DHE only-5 ug/ml (Fig
ure 15B), light only-1 minute (Figure 15C) , and light
only-5 minutes (Figure 15D).
Large numbers of trypan blue stained-dead cells
were present in the light and DHE treated groups (Figures
15E, 15F).
Mean percent viability, along with other distribu
tion statistics, was calculated for each group at each
time period. Results appear in Table 6 and are displayed
graphically in Figure 16. Over time, mean viability of
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Pre-treatment, mean cell viability was 86.9% on Day
2 post plating, and 89.5% on Day 3. At one hour post
treatment and irradiation, mean cell viability was
between 87.1% and 93.5% in the untreated, DHE only, and
light only groups. The mean cell viability decreased and
showed values from 58.7% to 1.8% with increasing light (1
to 5 minutes) and increasing DHE (1 to 5 ug/ml).
At 24 hours (Day 4), the mean cell viability of the
"control"
groups was between 85.1% for light only at 5
minutes to 92.5% for light only at 1 minute. The light-1
minute and DHE-1 ug/ml group showed a mean viability of
67.5% which was increased as compared to Day 3, 1 hour
post irradiation. This indicates that the cells were
increasing their numbers of live cells.
The mean viability of the light-1 minute and
DHE-
1,5 ug/ml treated groups decreased as compared to Day 3,
1 hour post irradiation and were significantly lower than
other groups. This is due to cells that were still
dying. The light-5 minutes and DHE-5 ug mean cell viabil
ity increased slightly.
At 96 hours (Day 7), there was an overall decrease
in mean cell viability. The cell medium was running out
80
of nutrients along with the build up of toxic and
inhibitory substances. The exception being the light-1
minute DHE-5 ug/ml which increased.
Finally, at 144 hours (Day 9) post irradiation,
mean cell viability continued to decrease in all groups,
except in the light-5 minutes, DHE-1 and 5 ug/ml groups.
Plots (Figures 17A-D) were created to show variance
and help explain differences between the mean cell viabil
ity of each group, at each time period post irradiation.
A comparison of differences of means was determined
by ANOVA and Student's t-test. The null hypothesis is
that the means are equal. For Day 3, one hour post
irradiation, there is no significant difference between
the control groups; in other words, the means are equal.
Light and DHE alone do not affect cell viability.
There is no significant difference (p > 0.05) between
"control"
groups and light at 1 and 5 minutes, DHE 1 ug/
ml groups. There is a significant difference (p < 0.05)
between the
"control"
groups and light 5 minutes, DHE





































FIGURE 17A. Variance plot of mean viability (%) of
attached cells, one hour post irradia
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FIGURE 17B. Variance plot of mean viability (%) of
attached cells, 24 hours post irradia




and 2 SE, (bar)



































FIGURE 17C. Variance plot of mean viability (%) of
attached cells, 96 hours post irradia




and 2 SE, (bar)
























FIGURE 17D. Variance plot of mean viability (%) of
attached cells, 144 hours post irradia




and 2 SE, (bar)




At 24 hours post irradiation (Day 4), mean cell
viability of all "control" groups was the same, as were
all the "treatment" groups. There was a significant
difference (p < 0.001) between the mean cell viability of
the
"control"
groups and of the treatment groups.
At 96 hours (Day 7) and 144 hours (Day 9) post
irradiation, there was no difference in the mean
viability except with the light-5 minutes, DHE-5 ug/ml
group [Day 7, p < 0.0001; Day 9, p < 0.05].
Viability
- Attached and Detached Cells
An experiment was carried out to determine the cell
viability in the wells of both attached and detached
cells. When cells were killed, they detached from the
tissue culture plate surface and floated in the medium.
Since the medium was aspirated and saved for catechola




The results of the experiment were tabulated in
Table 7 and are shown in Figure 18. Variance plots were
constructed and appear in Figures 19A and 19B.
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TABLE 7
Viability (%, mean +1 CV) of Attached and
Detached Cells at 1 and 24 Hours Post Treatment
Group 1 Hour 24 Hours
C* 86 92
LI 96 + 0.01 94 + 0.04
L5 96 + 0.02 94
L1D1 94 + 0.01 84 + 0.09
L5D1 86 + 0.03 87 + 0.02
D5* 89 90
L1D5 48 + 0.04 14 + 0.39
L5D5 4+0.82 9+0.25
L = Light for 1 or 5 minutes
D = DHE concentration, 1 or 5 ug/ml
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FIGURE 18. Mean viability (%) of attached and





































FIGURE 19A. Viability of attached and
detached




- +1 and 2 SE, (bar)





































FIGURE 19B. Viability of attached and detached





- +1 and 2 SE, (bar)












Comparison of Viability of Attached Only
and All Cells - Attached and Detached
1 Hour 24 Hours




+ 1SD X + 1SD X + 1SD
91 86 89 92
+6.6 +7.2
87 ND* 91.1 ND
+14.0 +5.8
88 89 88.1 90
+7.4 +5.9
93.5 96 92.5 94
+3.0 +1.0 +5.4 +3.8
91.5 96 85.1 94
+7.1 +1.9 +15.4 +0.0
**58.7 94 67.5 84
+25.5 +0.9 +31.5 +7.6
**38.4 86 **30.5 87
+24.6 +2.6 +7.3 +1.7
***24.4 48 16.7 14
+20.0 +1.9 +17.0 +5.5
1.8 4 6.0 9
+3.4 +3.3 +6.6 +2.2




At one hour post, the cell viability was 86% for
the control group. The mean cell viability at one hour
post irradiation was between 86% and 96% for all groups
except for L1D5 and L5D5
, which are 48% and 4%. The
differences between these and other groups are evident.
At 24 hours post irradiation, the cell viability of
the control group was 92%. The mean cell viability for
all groups except L1D5 and L5D5 was between 84% and 94%.
The mean cell viability for L1D5 and L5D5 is 14% and 9%,
respectively. The difference between these groups and
the others is evident.




, and L1D5 at one hour post irradiation and in
L5D1 at 24 hours. This means that in these groups, cells
that were detached were not dead as determined by trypan
blue dye exclusion.
A comparison of these results to the viability of
only attached cells is shown in Table 8 (page 91) only.
There was no difference in the viability except between
groups L1D1 , L5D1 , and L1D5 at one hour.
92
Catecholamine Analysis
Catecholamine dopamine, epinephrine, and norepin
ephrine levels were measured in tissue culture medium
removed from wells containing growing C1300 MNB cells.
p
The differential catecholamine Cat-A-Kit assay system
was used for all determinations. Each kit assayed 22
samples, including normal human plasma control.
Seventy samples of medium were assayed using ten
kits. Samples were from two replicates, one that used a
DHE concentration of 1 ug/ml and one that used a DHE
concentration of 5 ug/ml. Samples from all wells and all
groups were included from each replicate.
Quality Control
Accuracy and precision of the catecholamine analy
sis was determined by measuring the concentration of
human plasma control provided in the test kit. Since the
assay has been developed
as a kit, it was expected that




All samples were run in duplicate. The mean
variation (+1 CV) of duplicates for all samples analyzed
was for dopamine (DA), 15.9%; epinephrine (E), 11.7%; and
norepinephrine (NE), 13.1%.
R
Amersham, the Cat-A-Kit manufacturer, reports that
the assay is linear between 2-20 and 3000 pg for a
50 1 sample. A check on linearity of the assay was
performed by analyzing human plasma control at dilutions
of 1:1, 1:5, and 1:10. Only two dilutions were made
because of the need to limit samples due to cost and
time. Two determinations were made at each dilution.
The mean value was used for comparison. Results appear
in table 9 and in Figures 20 and 21. To verify true
linearity, serial dilutions (more than three) should be
made over the range of concentrations expected.
Referring to Table 9, one can see a comparison of
the measured and expected values. The values matched at
dilutions of 1:5 and 1:10 for epinephrine and norepin
ephrine, but are low for dopamine. At 1:1, the measured
result is the same as the expected result.
The line plots in Figure 20 show that the determina
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FIGURE 20. Linearity of Cat-A-Kit assay. Serial
dilutions (1:5, 1:10) of human plasma
control each point for NE and E repre
sent the mean of 2 points. DA single
point. Dashed lines show assay detec
tion limit as calculated by 2x back
ground counts of blank.
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for epinephrine and 77.7 and 770.7 pg/ml for
norepinephrine. The plot for dopamine is not linear
because low values are obtained at low concentrations
(sensitivity and detection limit). An expanded scale of
0 to 150 pg/ml appears in Figure 21.
Amersham reports that the assay is sensitive to
twice the radioactivity of the sample blanks. They
report values of 1.2 pg NE/cpm blank, 0.9 pg E/cpm blank,
and 7.1 pg DA/cpm blank (cpm
-
counts per minute). The
realized assay detection limit (2x radioactivity
of
blank) is NE 2.4 pg/0.05 ml (2-5
pg/0.05 ml), E 1.8
pg/0.05 ml (2-5pg/0.05 ml), and DA 14.2
pg/0.05 ml (15-20
pg/0.05 ml). This means that the assay is
sensitive to




0.67 pg/cpm DA, 0.83
pg/cpm E, and 1.08 pg/cpm NE .
Sample blanks had cpm's of
225 for DA, 92 for E, and
106 for NE. The realized
calculated experiment assay
detection limit is 335 pg/ml
for DA, 153 pg/ml E, and 228
pg/ml for NE.
Although results of the
diluted human plasma
control show detection to approximately
70 pg/ml for E
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and NE, this is closer to the limit determined from
pg/Blank 1 x cpm, that were equal to 61.6 pg/ml for E,
114.5 pg/ml for NE
, and 150 pg/ml of DA.
Accuracy of the assay was determined by measuring
concentration in human plasma control and comparing the
results to values given by Amersham. These results
appear in Table 10. Two lots of the assay kit were
used. The values +150 match.
It is important to show agreement between replicate
measurements. Precision was determined for Cat-A-Kit
assay. Inter-assay variation between runs and between
kits for human plasma control appears in Table 11.
Pueler developed the single isotope radioenzymatic
assay. His variation is reported as well as that of
Amersham.
The experimental variation
(+ CV) between run,
combined lots, was 13.4% for NE , 10.8%
for E, and 10.1%
for DA. These are the same as
Amersham'
s and Pueler 's
measured variation.
The experimental between kit
variation (+ CV) was
11.2% for NE, 6.4% for E, and 7.7%



































Inter-Assay Variation (CV) Between-Run and Between Kit
of Human Plasma Control
Between-Run DA E NE
Pueler 15.5 9.4 10.3
Amersham 12.6 13.5 7.8
Experimental Lot 7A (n=2) 3.6 5.6 11.0
Lot 8A (n=7) 7.7 9.6 10.9
Combined 10.1 10.8 13.4
Between Kit
Pueler 15.5 9.4 10.3
Amersham 12.6 13.5 7.8
Experimental (n=5) 7.7 6.4
11.2
101
for NE was the same as obtained by Pueler and greater
than
Amersham'
s. The experimental variation was less for
E and DA than obtained by Pueler and Amersham.
Within-run variation was not determined due to
limited number sample runs per kits. Historically,
Pueler and Amersham report variation (+ CV) between 2.7
and 4.6% (Table 12).
The Cat-A-Kit assay is sensitive and accurate with
acceptable (10%) precision.
Experimental Results
Results of differential catecholamine analyses of
tissue culture media appear in Tables 13-19. Medium over
cells from individual wells was sampled. One sample per
well was analyzed for catecholamines. The results of the
pre-treatment concentrations of DA, E, and NE at 0, 2,
and 3 days post plating are shown in Table 13.
Remembering that experimental detection limits
(pg/ml) for catecholamines were 335 pg/ml for DA, 153
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0* 17 0 5
2 130 16 0











tAll results below detection limit of assay
?Assayed once
**Same as 1 ug value, listed for comparison
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TABLE 14
Concentration of Dopamine (pg/ml) in Medium
DHE Concentration - 1 ug/ml
Days C Dl LI L5 L1D1 L5D5
3 post 127 31 0 4 0 0
4 66 14 141 7 0 0
7 31 0 42 429| 0 0
9 78 0 40 46 0 0
C = Control
Dl = Drug only, 1 minutes
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D1 = Light 1 minute, DHE 1 ug/ml
L5D5 = Light 5 minutes, DHE 5 ug/ml
Cells Exposed to lgug DHE/ml for 2 Hours
and 30 mW/cm Argon Laser
|Only result above detection limit of assay
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TABLE 15
Concentration of Dopamine (pg/ml) in Medium
DHE Concentration - 5 ug/ml
Days C D5 LI L5 L1D5 L5D5
3 post 485| 27 183 65 177 44
4 0 14 111 9 0 0
7 0 168 180 156 170 0
9 0 95 60 315t 128 0
C = Control
D5 = Drug only, 5 minutes
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D5 = Light 1 minute, DHE 5 ug/ml
L5D5 = Light 5 minutes, DHE 5 u g/ml
Cells Exposed to 5ug DHE/ml for 2 Hours
and 30 mW/cm Argon Laser
tOnly results at or above detection
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TABLE 16
Concentration of Epinephrine (pg/ml) in Medium
DHE Concentration - 1 ug/ml
Days Dl LI L5 L1D1 L5D1
3 post 42 30 18 23 4 8
4 29 20 18 10 17 0
7 25 0 26 742| 7 5
9 23 41 7 0 0 4
C = Control
Dl = Drug only, 1 minute
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D1 = Light 1 minute, DHE 1 ug/ml
L5D1 = Light 5 minutes, DHE 1 ug/ml
Cells Exposed to Uug DHE/ml for 2 Hours
and 30 mW/cm Argon Laser




Concentration of Epinephrine (pg/ml) in Medium
DHE Concentration - 5 ug/ml
Days D5 LI L5 L1D5 L5D5
3 post 0 0 21 29 39 421t
4 0 0 46 22 272| 23
7 0 35 37 16 52 0
9 609t 35 30 28 17 157t
C = Control
D5 = Drug only, 5 minutes
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D5 = Light 1 minute, DHE 5 ug/ml
L5D5 = Light 5 minutes, DHE 5 ug/ml
Cells Exposed to 5ug DHE/ml for 2 Hours
and 30 mW/cm Argon Laser
tOnly results at or above
detection limit of assay
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TABLE 18
Concentration of Norepinephrine (pg/ml) in Medium
DHE Concentration - lp g/ml





3 post 506t 392| 678| 535| 337|
4 301t 374t 25 377t 682f
7 104 0 423 253| 431|
9 10 4 0 0 0
C = Control
D5 = Drug only
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D1 = Light 1 minute, DHE 1 ug/ml
L5D1 = Light 5 minutes, DHE 1 ug/ml
Cells Exposed to l2ug DHE/ml for 2 Hours
and 30 mW/cm Argon Laser
tOnly results at or above
detection limit of assay
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TABLE 19
Concentration of Norepinephrine (pg/ml) in Medium
DHE Concentration - 5 u g/ml
Days C D5 LI L5 L1D5 L5D5
3 post 7 0 0 8 5 743t
4 0 0 110 0 148 26
7 0 49 0 26 25 0
9 388| 0 0 8 21 664|
C = Control
D5 = Drug only
LI = Light only, 1 minute
L5 = Light only, 5 minutes
L1D5 = Light 1 minute, DHE 5 ug/ml
L5D5 = Light 5 minutes, DHE 5 u g/ml
Cells Exposed to 52u g DHE/ml for 2 Hours
and 30 mW/cm Argon Laser
fOnly results above detection limit of assay
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Concentration of Dopamine (Tables 14, 15), Epin
ephrine (Tables 16, 17), and Norepinephrine (Tables 18,
19) are reported by group and post treatment day.
In reviewing the data, most results are below the
the detection limit. The data above detection limits was
variable and no interpretation could be made. The null
hypothesis was that the levels of catecholamines in all
groups are equal when sampled at the same time. One
cannot reject the null hypothesis.
Ill
DISCUSSION
It was expected that the chosen levels of DHE and
argon laser light would alter cell metabolism and kill
some of the C1300 MNB cells. The robust experimental
design measured two concentrations of DHE that were in
the range encountered in malignant tissue in vivo, and
two doses of argon light that were at levels used for
laser induced fluorescence of DHE for detection of malig
nant tissue.
Cell Morphology
Changes in cell morphology with both treatment and
with time were expected. Structure is related to func
tion.
Exposure with light only-5 minutes caused vacuoles
to appear. Damage and death occur from direct damage to
DNA (Deoxyribonucleic acid) and other organic
molecules
(33).
There is photoproduction of toxic compounds in
tissue culture media (33) such as the formation of
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hydrogen peroxide, intramolecular polymerization, trypto
phan is oxidized to N-formylkynurenine and tyrosine is
broken into various cleavage products.
In the DHE and light treated groups, pyknotic
granules were seen. These are changes in size of golgi
apparatus, formation of irregular nuclear membranes,
vacuoles (38,39,44,45), and possibly DHE itself.
Cell Growth
In the light and light-DHE treated groups, attached
cell numbers decreased because the damaged cytoskeleton
(biopolymers) detach from extracellular protein/polymer
matrix, thus cells break away from the plate surface.
This explains the loss of cells one hour post wash, post
irradiation groups. Since cells in these groups are
damaged, cell reproduction is impaired or halted. So,
with increasing time (growth curve), cell numbers remain
the same, increase slightly, or decrease. Cell death
with time is because medium is running out of nutrients.
Changes in viability of cells can be explained
because of similar effects. It was assumed that all
floating cells were dead. This was the case for most
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groups~Light-5 minutes, DHE 1 wg/ml and Light-1 minute,
DHE-5 ug/ml at one hour. Some of these cells did not
stain with trypan blue, thus are viable. This can be
explained by the fact that photodynamic effects take
time. Cell machinery has been impaired and biopolymers
in the cytoskeleton damaged, but cell membrane has not
degraded, yet.
Experimental Problems
Problems were encountered in performing the experi
ment. Experimental replicates were lost because the
laser broke and cultures became contaminated with fungus.
This left 9 out of the 14 experiments for data collection
and interpretation.
Catecholamine Analysis
The radioenzymatic assay kit for differential cate
cholamines is a labor intensive, expensive analysis. The
analysis requires two days of laboratory manipulations
such as incubation, extractions, and centrifugation, and
one day for B-counting in a liquid scintillation counter.
The cost and time is why a limited number of
samples were analyzed. The cost per sample reagents,
kits, equipment, and labor was $110/medium sample.
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Problems with the Assay
The Cat-A-Kit is labor intensive. Most steps are
critical. Thus, one must adhere to proper technique in
order to yield accurate and precise results. One out of
10 assay runs was rejected due to low counts. Problems
associated with running the assay were:
In two runs, there were low counts (CPM) in all
samples. This was because of inadequate extraction of
derivatives in and out of organic and aqueous layers.
This problem was resolved by mixing exactly for the
specified time. Systematically low counts were
multiplied by a correction factor of yield results in one
run.
In one run, failure of the shaking water bath
occurred during incubation. This caused a slower rate of
3
the enzymatically controlled transfer of H-SAM to the
catecholamines. The samples showed systematically low
counts.
Background counts of the blanks were high in two
runs. This was due to backwash of radioactive material
left in the thin layer chromatography developing tank.
More careful and repeated washing with greater volumes of
toluene eliminated the radioactive material. The back
ground counts of the blanks dropped by one-half.
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Interpretation of Catecholamine Results
Dopamine is present in cytoplasm of cells. Cate
cholamines, NE and E, are synthesized, stored and taken
up into granules at the end of neurite-like extensions.
Any impairment of ATP (adenosine triphosphate)
metabolism results with eventual failure of the cell and
granule membranes. Light and DHE damages proteins and
oxidizes lipids in the membrane.
Catecholamine levels were expected to change in the
light-5 minutes and the light and DHE treated groups.
Concentration of DA, E, and NE would increase in the cell
medium if the cell membranes were ruptured and stored
catecholamines were released. The concentration at 1 and
24 hours would be expected to be higher.
Another alternative way that concentration would
drop post treatment is if catecholamine metabolism was
impaired or membrane proteins damaged inhibiting
dopamine-
B-hydroxylase a membrane associated enzyme function.
Cell growth may have continued
with impaired
catecholamine metabolism. Results of growth and cell
viability suggest that in the Light
and DHE treated
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groups, both cell reproduction and cell kill occurred.
Therefore, it was expected that catecholamine production
was also impaired.
Catecholamines could have been oxidized by oxygen
In ambient air or photo-oxidized medium constituents.
This would have led to a decrease in catecholamine levels
with time.
No interpretation can be made since the concentra
tion of catecholamines in medium from independent sample
wells were highly variable, and some values were at or
below the detection limit of the assay.
Experimental Design
- Future Work
Growing and studying cells in tissue culture
plates
required fastidious techniques to control
variables.
Time intervals were limited due to the small volume
of
medium in each well of the 48 well plate. Treating and
changing the medium at Day 3 was designed
to extend the
time interval and maximize cell growth post
treatment.
When studying a biochemical, using
an in vivo model
(i.e. a mouse) would simplify
the experiment both in
supply of nutrients,




Argon laser light at the power density of 30 mW/ cm
2 9
and energy densities of 1.8 J/cm and 9.0 J/cm
significantly changed cell morphology, numbers, and
viability only when used with DHE at 5 ug/ml at 1, 24,
96, and 144 hours post irradiation. The L5D5 group was
the most severely affected at all sampling times.
Argon light alone did not alter cell morphology,
numbers, or viability, except for morphology at 1 hour
post irradiation, when cells were treated with light for
2
5 minutes (9 J/cm ).
Cell media was assayed for the catecholamines
dopamine, epinephrine, and norepinephrine. Only a few
samples were at or above the detection limit of the
Amersham
Cat-A-KitR
assay. Of these, results were
variable. Therefore, no interpretation can be made
concerning catecholamine production of
C1300 MNB in this
experimental model. It could not be concluded from the
data that catecholamines would be useful as a specific
marker of tumor impairment or death.
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At the low energy of levels argon laser light and
DHE used for tumor detection, the guarded inference can
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APPENDIX 1
AMERICAN TYPE CULTURE COLLECTION
12301 Parklawn Drive Rockville, Maryland 20852
COLLECTION OF CELL LINES
ATCC No.:
CCL 1*7
Name. NB41A3 (Neuroblastoma, C-1300, Mouse)
Culture Medium:
Ham's F-10 medium, 82.5%; horse serum, 15%; fetal bovine serum, 2.5%.
Fluid Renewal: 2-3 x weekly Subculture Procedure:
Remove medium, add fresh
0.25% viokase for 2-3 minutes, remove and let culture sit for 10-20 minutes at room
temperature. Add fresh medium, aspirate, and dispense into new flasks. A subcultivation
ratio of 1:2 to 1:4 is recommended.
Part A. FROZEN CELLS
Freeze: 5924 Vol./Ampule:
liP_ml Passage No.: 46 Date Frozen: lf& Cells/ml.: 2-7
x 10
Expected Viability(%): 90-95% Population Doublings: nZs
Recommended Handling Upon Receipt: Initiate culture as soon as possible upon receipt. Thaw by rapid
agitation in
37
C water bath. See instructions on back. ,,,.,,.. r ,*
...
,.,_,. 1:12 dilution of ampule contents.
Recommended Inoculum Upon Thawing:
Part B. FLASK CULTURES
No. Cells Seeded Per Culture: ll Passage No.:
Recommended Handling Upon Receipt:
Monolayer Cultures: The bottle is completely filled with medium to prevent loss of cells in transit. Remove
all of the medium (which can be saved and used as fresh medium) except for a sufficient volume to cover the
floor of the flask. Incubate at 37C. Sometimes in transit the cultures are handled roughly and most of the
cells become detached and float in the culture medium. If this has occurred remove the entire contents of the
flask and centrifuge at 300 x g for 1 5 minutes. Draw off the
excess supernatant medium, resuspend the cells
in 10 ml of the culture medium and plant the entire cell suspension in a single flask of suitable size (ca 25 sq.
cm.).
Suspension Cultures: The culture flasks have been completely filled with medium for shipment. Remove






C-1300 Neuroblastoma Cells in Male A/J Mice
Purpose: 1. To enhance growth characteristics of cell line by
passing through a host animal.
2. To establish in vivo tumor model.
Materials: T-25, 75 flasks
Ham's F-10 with glutamine with serum
50 ml centrifuge tubes, plastic, sterile






C-1300 NB cells, ATCC CCL147 (NB41A3)
Methods 1: Tissue Culture (T.C.) to Mouse (C.J. McCormack)
1. Suspend cells in T.C. flask by scraping with rubber
policeman .
2. Pipet up and down the total volume of the flask (x5) to
mix cells.
3. Centrifuge cells at low G's 5 minutes in T.C. centrifuge
tubes (50 ml) .
4. Decant supernatant.
5. Resuspend all cells into a single vial, medium Ham's F-10
without serum.
6. Perform cell count.
7. Report total live cells/ml.
a
8. Centrifuge, resuspend in medium to get 1 x 10 cells/0.1
ml .
9. Inject 0.1 cc into mouse.
10. Grow until 2 cm longest, measured every two days.
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Methods 2: Excision of Tumor for In Vivo or In Vitro Passage
1. Sacrifice mouse by cervical dislocation (ideal tumor size
is less than 2 cm longest diameter).
2. Shave area around tumor mass; wipe off loose hair. Dip
entire mouse into 70% ethanol or wet totally with 70%
ethanol .
3. Wipe down or dip tips of instruments in 95% (or 70%) ETOH
and pass through flame to burn off. Excise skin in half-
circle around mass. Use scissors to dissect skin off of
mass and reflect back the skin flap.
4. Remove non-necrotic chunks of tumor and put into medium
(10 cc in petri dish).
5. Press chunks through stainless steel mesh with plunger of
10 cc syringe.
6. Using 10 cc syringe, flush cell suspension and fibrous
chunks up and down several times, then draw into syringe
and put on 18 g or 21 g needle. Stand on end for 1 minute
to settle out chunks.
7. Bend over needle and express cell suspension into centri
fuge tube, leaving last 1 cc containing chunks behind.
8. Perform cell count sample and, while counting, spin cells
down in centrifuge. Best is 200 to 300 x G for 4 to 5
minutes, but can use 500 x G for 1-1/2 minutes.
9. For injection into mice, resuspend in Ham's F-10
+ Pen/
Strep, inject proper number of cells in volume of 0.10 cc
or 0.05 cc subcutaneously.
For tissue culture, all steps from #3 to #7 should be
performed in sterile hood.
APPENDIX 3
Calibration Procedure of COULTER COUNTER Model Z
A. Choosing Control Setting
1. Prepare a dilute suspension of the calibration standard
(MICROSPHERES 14.71 micrometer dia.); place a beaker of
this dilution on the Sample Platform.
2. Open the Control stopcock.
3. Set the threshold dial at 10.
4. Adjust the 1/AMPLIFICATION switch and 1/APERTURE CURRENT
switch so that the pulse pattern on the oscilloscope is
about one-third the height of the screen (1/AM:4,
1/AP:4).
5. Run a series of five counts. Record each answer. Then
find the average (5487.8).
6. Divide this average by two to get the half-count
(2743.9). The point on the Threshold Dial where this
half-count can be taken will approximate the same point
representing the Median Particle Volume (or Diameter).
7. Rotate the Threshold Dial until the threshold appears to
coincide with the Median Volume on the screen. Then run
a succession of five or more counts, record the answers,
and find the average.
8. This average should equal the half-count previously com
puted. If not, raise or lower the Threshold Dial accord
ingly. Run five more counts and find the average again.
When the half-counts have matched the computed
half-
counts, the median has been found (Threshold: 37.5).
B. Calibration Computation
Calibration constant, K, can now be determined by the
formula:
V = average volume of the known system
I = the 1/APERTURE CURRENT Switch setting
A = the 1/AMPLIFICATION Switch setting
T = the setting of Threshold for
half-count
With the calibration constant, any unknown volume, V, can be




Comparison of Cell Counts - Manual versus Automatic










1. Cells of stock solution were counted.
2. Cell solution was diluted over the range of counts
seen during the experiment.
3. Counts made both on the hemacytometer and the Coulter
counter ZF after (1:100 dilution).
4. Results on the Coulter read absolute cell number per
sample, 0-5000 counts.
5. Cell counts as cells/ml reported for both methods.
6. Plots made cell count automatic versus cell count
manual .
Results :
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MANUAL (CELLS/ML x 1000)
A4.4
REFERENCES:
1. Reynolds, C.P., D.C. German, A.G. Wienberg, R.G. Smith.
Catecholamine fluorescence and tissue culture morphology:
Technics in the diagnosis of neuroblastoma. American
Journal of Clinical Pathology 75(3) :275-282 , 1981.
2. Sumners, C, M.I. Phillips, M.K, Raizada. Rat brain cells
in primary culture: Visualization and measurement of cate
cholamines. Brain Research 264:267-275, 1983.
3. Lindvall, 0. and A. Bjorklund. The glyoxylic acid fluores
cence histochemical method: a detailed account of the
methodology for the visualization of central catecholamine
neurons. Histochemistry 39:97-127, 1974.
APPENDIX 5
PROTOCOL
Preparation of Cells for Catecholamine Analysis
PURPOSE: To determine catecholamine levels in C1300 Neuroblas
toma (mouse) cells in tissue culture. Particularly,
levels of norepinephrine (NE) and dopamine (DA).
MATERIALS:
Cells:
NB41A3 C1300 NB cells
Reagents :
ice cold phosphate buffered saline, pH 7.4 (Gibco)
0.2 M perchloric acid (Mallinckrodt)
10 mM (in 0.2 N perchloric acid) dithiothreitol (Sigma)
1.0 M potassium hydroxide (to neutralize) (media only)
Equipment :
Test tubes
Pipets - serological 5 ml








1. After removal of growth medium cells are washed lx with
ice cold PBS, pH 7.4.
2. Cells are scraped from tissue culture flask using a rubber
policeman.
3. Cells are then transferred to test tubes.
4. An aliquot is removed for cell count and volume in tube is
noted and recorded.
5. Cells in test tubes centrifuged supernatant discarded.
APPENDIX 4
Fluorescent Catecholamine Staining
PURPOSE: To identify and document, visually and photographic
ally, catecholamine (blue green) fluorescence and





American optical fluorescent microscope BG12 exciter
filter 405/20 nm band pass filter RKG 455 beam splitting
mirror. 460 nm long pass suppression filter.
'








- 50% in HgO (#8497, Kodak), 500 gms
*
Sucrose (S-5, Fisher Scientific)
*












Mouse C-1300 NB ATCC 147 NB41A3
Methods (Combined techniques of Reynolds
and Sumners):
1. 4 and 7 day old cultured cells
are grown on rectangular
glass cover slips.
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2. The cover slips with cells are removed from the tissue
culture flasks and rinsed with PBS, pH 7.4 and
3. immediately placed in a 2% buffered glyoxylic acid solu
tion (SPG) (4C) for 5 minutes.
Excess glyoxylic is removed and cover slips dried with
compressed air for 10 minutes.
Cover slips are heated in oven 80C for 10 minutes.
Cover slips are cooled and mounted on glass slides with
liquid parafin.
Slides are viewed on A.O. fluorescence microscope - A.O.
setting:
Exciter filter BG12
Barrier filter GG 475
Dichroic supp. filter 450 nm
Control slides, cells immersed in cold PBS treated and
mounted to look at background fluorescence.
Resulting all-catecholamine fluorescence and phase con









1. If blue green fluorescence is present, where, in neurites.
2. Is the mount of fluorescence different in the 4 day and 7
day cells (neurites)
-

















Positive Control of CA Fluorescence
1. Preparation of SPG solution: Sucrose (5.1 g) , anhydrous
KH2P04 (2.4 g) , and glyoxylic acid (0.75 g) were dissolved
in 40 ml of distilled water. The pH of the solution was
adjusted to 7.4 with 2N NaOH, and the volume adjusted to
75 ml with distilled water.
2. Incubating the cultured cell line C-1300 NB in 4 mg/ml of
dopamine in Ham's for 5 minutes on slide.
3. The cells were washed once with Ham's and slide was dried
quickly and gently with compressed air.
4. Slides were dipped three times (one dip/sec) in SGP solu
tion. The slides were placed at a 45 angle on a paper
towel and the excess solution was blown off the slides
with compressed air.
5. A drop of mineral oil was placed on the cell, over which a
cover slip was mounted.
6. The slides were heated in an oven at 95 C for exactly
2-1/2 minutes and allowed to cool at room temperature.
7. The slides were examined with fluorescent microscope.
A4.4
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APPENDIX 5
PROTOCOL
Preparation of Cells for Catecholamine Analysis
PURPOSE: To determine catecholamine levels in C1300 Neuroblas
toma (mouse) cells in tissue culture. Particularly,
levels of norepinephrine (NE) and dopamine (DA).
MATERIALS:
Cells:
NB41A3 C1300 NB cells
Reagents :
ice cold phosphate buffered saline, pH 7.4 (Gibco)
*
0.2 M perchloric acid (Mallinckrodt)
*
10 mM (in 0.2 N perchloric acid) dithiothreitol (Sigma)
*
1.0 M potassium hydroxide (to neutralize) (media only)
Equipment :
Test tubes
Pipets - serological 5 ml








1. After removal of growth medium cells are washed lx with
ice cold PBS, pH 7.4.
2. Cells are scraped from tissue culture flask using a rubber
policeman.
3. Cells are then transferred to test tubes.
4. An aliquot is removed for cell count and volume in tube is
noted and recorded.
5. Cells in test tubes centrifuged supernatant discarded.
A-5.2
6. 300-400 ul of 0.2 N perchoric acid/10 mM dithiothreitol
solution is added to test tubes to deproteinize the
tissue.
7. Cells are homogenized.
8. 10 ul sample is obtained for protein determination (ck
amount chem lab) .
9. The remainder solutions of homogenized cells are centri
fuged at 8000 g, 4C for 20 minutes.
10. Individual supernatants are removed, volumes noted,
freeze dried and stored at -80C until assayed for NE or
DA.
11. Samples reconstituted with 20 ul distilled HgO.
REFERENCE:
1. Sumners, C, M.I. Phillips, M.K. Raizada. Rat brain cells
in primary culture and measurement
of catecholamines.
Brain Research 264:267-275, 1983.
ADDENDUM:
Solution preparation
0.2N perchloric acid solution HCL04
M.W. 100.46
70% perchloric and stock
N = grams solute weight volume %
= wt. grams solute X 100
liter sin x eq. wt . volume
sin ml
How many ml of 70%
perchloric acid stock solution do I need to
detail in 10 ml to get a 0.2 N sin?
70% w/v = ?N
W/V = 70 grams 700 grams
100 ml 1000 ml x i
= 0.7N
A-5.3
To get 0.2 N 1:3.5 dilution of 0.7 N
or
35 ml = 10 ml HCL04/25 ml TD water = 0.2 N HCL04
Now to get 10 mM dithiothreitol in 0.2 N HCL04
N.W. 154.3 (5 gms)
No. mmol = grams of species x 1000
gm wt
10 = gm x 1000
154.3
gm = 10 (154.3)
= 1543 = 1.543 g/L
Tooo" Tooo"
.010 M = gms GMW/L
or mg M.W./L
1 mM = .156 g/L
10 mM = 1.56 g/L
0.2 N HCL04 total volume/batch
- 35 ml
















system provides a very sensitive, reliable and precise
quantitative determination of adrenaline (epinephrine),
noradrenaline (norepinephrine) and dopamine in
urine, plasma and other biological samples. The
system utilizes the enzyme catechol-O-
methyltransferase (COMT) to catalyse the transfer of a
[3H]-methyl group from tritiated
S-adenosyl-L-
methionine ([3H]-SAM) to the hydroxyl group in the
3-position of the catecholamines, adrenaline
(epinephrine), noradrenaline (norepinephrine) and
dopamine. Separation of the resulting products,
[3H]metanephrine, [3H]normetanephrine and
[3H]methoxytyramine is achieved by thin-layer
chromatography. The band corresponding to
[3H]methoxytyramine is eluted and counted directly,
whereas the bands containing [3H]metanephrine and
[3H]normetanephrine are eluted and converted to
[3H]vanillin by periodate oxidation prior to counting.
As described, the assaymeasures all three
catecholamines separately. However, the assay system
can also be used tomeasure 'total
c t cholamines'
(adrenaline plus noradrenaline) in biological samples.
Adrenaline (epinephrine) and noradrenaline
(norepinephrine) may be measured in the range 2-5pg
and dopamine in the range 15-20pg per 50gl sample.
Each pack contains sufficient material for 90 assay
tubes.
Precise and accurate
Small sample size: i0-50ul
No prior extraction required
Measures total or individual catecholamines.
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Introduction
The three catecholamines adrenaline, noradrenaline
and dopamine have different physiological functions
varying with their anatomic location. In the nervous
system, noradrenaline and dopamine act as
neurotransmitters, whereas adrenaline is the major
hormone of the adrenal medulla. Catecholamines are
known to serve as reliable markers of sympatho
adrenal activity in man"-21. Measurement of
catecholamines can assist in elucidating the role of the
sympatho-adrenal system and help in the diagnosis
and management of hypertension, coronary disease
and acute myocardial infarction. Catecholamine levels
are significantly increasedwhen
phaeochromocytomas are present and their
measurement in plasma can provide clinically useful
datawhen phaeochromocytoma is suspected'31. The
availability ofAmersham's catecholamines assay
system will facilitate the evaluation of the physiological
role of these important biogenic amines.
Summary off the assay
In 1973, Passon and
Peuler1" described an innovative
single isotope assay for noradrenaline and adrenaline
which accuratelymeasured these catecholamines in
less than one ml of plasma, required less than two days
to complete, and provided sensitivity of less than
200pg of either noradrenaline or adrenaline. Their
assay utilized the enzyme
catechol-O-
methyltransferase (COMT) to catalyze the transfer of a
[3H]-methyl group from S-adenosyl-L-[me?riy/-3H]
methionine (3H-SAM) to noradrenaline and adrenaline.
The resulting products, [3H]normetanephrine and
[3H]metanephrine, respectively, were isolated by
thin-layer chromatography. Each labelled derivative
was converted by periodate oxidation to [3H]vanillin and
extracted. The radioactivity attributable to each
catecholaminewas determined by liquid scintillation
counting.
The assay for catecholamines described here follows
the basic principles of Passon and Peuler. Extensive
modifications of their methodology produced the
following improvements:
1) The assay will measure dopamine in addition to
noradrenaline and adrenaline.
2) The sensitivity of the assay is in the range 2-5pg for
noradrenaline and adrenaline and 15-20pg for
dopamine per 50ul sample.
3) Assay time has been significantly reduced.
4) As little as 10-50ul of biological fluid is required.
The biochemical principles of the assay are
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Figure LCOMT-Catalyzed conversion of dopamine,
noradrenaline and adrenaline to corresponding
[3H]methoxy derivatives.
Dopamine, noradrenaline and adrenaline are
simultaneously converted to their corresponding
meta
[3H]methoxy derivatives by the catalytic action of a
partially purified preparation of COMT in the
presence
of[3H]-SAM.
Following the enzyme-catalyzed O-methylation of the
catecholamines, the catecholamine derivatives are
extracted, and separated by thin layer
chromatography. The isolated catecholamine
derivatives, [3H]normetanephrine and
[3H]metanephrine are converted by periodate







r = ch3 3H-Metanephrlne
Figure 2. Periodate oxidation of normetanephrine and
metanephrine.
The radioactivity in each extract is proportional to the
amount of noradrenaline or adrenaline in the sample
being analyzed. Since 3-methoxytyramine is not
susceptible to the periodate oxidation, this chemical
step serves as the means for differentiating
[3H]3-methoxytyramine (dopamine) from the other
two catecholamines.
Assaymethodology
Contents of the assay system
Vial 1 Standard solution
Vial 2 Stabilizing solution
Vial 3 Buffer solution
Vial 4 Tracer ([3H]-SAM)
Vial 5 Enzyme (COMT)
Vial 6 Stopping solution
Vial 7 Sodiummetaperiodate
Vial 8Glycerol
















Remove one vial from kit andmaintain below -20C in order to avoid
unnecessary Ireezing and thawing.
Amersham's catecholamines assay system provides
sufficient reagents for 90 assay tubes. The reagents are
stable onlywhen stored below
- 20C in a
non-defrosting freezer. The vials should be removed
from the package for thawing and should be refrozen
as rapidly as possible.While thawed, vials 1,4,5 and 9
should be kept in ice.
The 90 tube kit contains two vials each of [3H]-SAM
(vial 4), COMT (vial 5), sodium metaperiodate solution
(vial 7) and glycerol solution (vial 8). Remove one each
of vials 4, 5, 7 and 8 from the kit and maintain below
- 20C in order to avoid unnecessary freezing and
thawing.
It is important that cross contamination of reagents not
be introduced into any tubes or onto any glassware.
Each cap should be replaced on the same reagent vial
from which it is removed.
Vial 1: standard solution
Vial 1 contains 500ul of a solution of i-noradrenaline,
L-adrenaline and dopamine at 100ug per ml in acidic
glutathione solution. Store below -20C.
The standard solution must be accurately diluted
1 : 10,000 to a concentration of 10ng/ml for each
catecholamine. This solution provides the standard for
the assay; 10ul volumes (100 picograms of each
catecholamine) will be used. Due to the instability of the
diluted standards, even when stored frozen151, this
diluted solution must be prepared immediately before
each use according to the assay procedure (step 4).
Vial 2: stabilizing solution
Vial 2 contains 500ul of acidic glutathione solution.
Store below -20C.
This solution must be diluted 1:10,000 in the same
manner as vial 1 above (assay procedure, step 4), and
should be made fresh daily. The diluted solution (10ul)
will be added to every assay sample except those
which receive an aliquot of the diluted standard
solution.
Vial 3: buffer solution
Vial 3 contains 2ml of a ready-to-use solution of Tris
buffer pH8 5 containing ethylene glycol-bis
(8-aminoethyl ether) N, N'-tetraacetic acid (EGTA) and
MgClj. Store below -20C.
This solution is used to buffer the enzyme reaction in
the assay.
Vial 4: tracer (pH]SAM)
Vial 4 contains S-adenosyl-L-[mefrty/-3H]methionine,
9 25MBq, 250gCi in HCI.ethanol (9:1), pH2-1. Two
vials of tracer are provided.
Considerable care should be taken to keep this vial in
ice during distribution of this radiochemical to the
reagent mixture, after which the vial should be
returned promptly to the freezer and stored below
-20C.
Vial 5: enzyme (COMT)
Vial 5 contains 500ul of a ready to use solution of rat
liver catechol-O-methyltransferase in Tris buffer
containing glutathione, benzylhydroxyamine
hydrochloride and dithiothreitol. Two vials of enzyme
are supplied. Store below -20C.
The COMT enzyme contained in this vial has been
isolated from rat liver and partially purified by
modification of the method described byAxelrod and
Tomchick'61. Enzyme activity is standardized in each
COMT preparation by utilizing this assay procedure.
The enzyme concentration is adjusted to provide, in
each 10ul aliquot, an excess activity for the purpose of
this assay Slow deterioration of activity may occur due
to repetitive thawing and freezing. However, when
stored frozen and used according to directions, the
excess activity is sufficient to ensure usefulness in this
assay until the expiry date.
Vial 6: stopping solution
Vial 6 contains 5ml of a ready-to-use solution of
normetanephrine, metanephrine and
methoxytyramine (each at 4mM) in borate buffer pH1 1
containing (ethylene dinitrilo) tetraacetic acid disodium
(EDTAdisodium). Store below -20C.
The stopping solution contains each of the products of
the enzymatic reaction to serve as carriers for the
radiolabelled reaction products. If a precipitate is
observed in vial 6, the vial can be gentlywarmed to
dissolve the precipitate.
Vial 7: sodium metaperiodate
Vial 7 contains 5ml of a ready-to-use solution of 4%
(w/v) sodium metaperiodate. Two vials of this reagent
are provided. Store below -20C.
Vial 8: glycerol
Vial 8 contains 5ml of a ready-to-use solution of 10%
(v/v) glycerol. Two vials of this reagent are provided.
Store below -20C.
In the event that microbiological growth is detected
upon thawing, vial 8 should be discarded. A fresh
glycerol solution can be prepared (1ml glycerin, diluted
to 10ml with glass-distilled, deionized water).
Vial 9: control plasma (human)
Vial 9 contains 1ml of control plasma with assayed
levels of the three catecholamines (see vial 9 value card
for concentrations) plus EGTA and glutathione. Store
below -20C.
The purpose of this reagent is to permit the user to
assess the performance of the kit in his laboratory by
obtaining results within the ranges specified on the
value card.
The catecholamine levels shown on the value card
were determined by replicate assays at time of Quality
Control release.
Note: If precipitate (fibrin) is observed upon thawing,
centrifuge and use supernatant.
Warnings and precautions
For In Vitro Diagnostic Use. Not for Internal or
External Use in Humans orAnimals.
1) Caution: radioactive material
The radioactive material may be received, acquired,
possessed and used only by authorized persons in
clinical laboratories or hospitals and only for in vitro
clinical or laboratory tests not involving internal or
external administration of the material, or the radiation
therefrom, to humans or animals. Its receipt,
acquisition, possession, use, transfer and disposal
are subject to the regulations and a general licence of
Atomic Energy Agencies*, or the competent official
organisation^
"In France-L'elimination des dechets radioactifs est
reglementee par la legislation en vigueur (avis aux
utilisateurs paru au Journal Officiel du 6 juin 1970). Le
SCPRI ou les organismes designes par lui, est seul
habilite a proceder a la prise en charge des dechets
radioactifs. [French)
*
In USA-US Nuclear Regulatory Commission or a
State with which the Commission has entered into an
agreement for the exercise of regulatory authority.
[English]
*ln Canada -Canadian Atomic EnergyControl Board.
[English]
*
In Canada - La commission de controle de lenergie
atomique du Canada. [French]
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tin France-Ministere charge de la Sante, CIREA,
SCPRI. [French]
*ln Germany- Fur die Bundesrepublik Deutschland:
Verordnung uber den Schutz vor ionisierenden
Stahlen (Strahlenschutzverordnung) vom 13.10.1976.
Bundesgesetzblatt 1, Nr. 125 (1976).
Unfallverhutungsvorschrift fur denGesundheitsdienst
(VBG 103) vom 1.4.1983. [German]
Instructions relating to the handling, use and
storage of radioactive materials
I) All operations should be carried out in restricted
areas by trained and authorized persons. Storage of
radioactive materials should be in specially designated
areas accessible only to authorized personnel.
ii) No smoking, eating or drinking should be allowed in
the storage or laboratory areas. Pipetting of reagents
must not be done by mouth.
ill) Care should be taken to prevent ingestion or
contact with skin and clothing. Use of gloves and
protective clothing should be in compliance with local
regulatory and laboratory procedures.Wash hands
thoroughly after manipulation of test materials.
Iv) Care should be observed to avoid contamination of
working areas. If contamination occurs affected areas
should be thoroughlywashed with an appropriate
cleaning agent, for example detergent. Contaminated
materialsmust be disposed of as radioactive waste.
2)WarningPotentially InfectiousMaterial
Human blood products provided as components of
this pack have been obtained from human donorswho
were tested individually and who were found to be
negative for the presence of Human Immunodeficiency
Virus (HIV/HTLV-III/LAV) antibody (Ab) as well as for
Hepatitis B surface Antigen (HBsAg) using reliable
methods.
As no test method can offer complete assurance that
Hepatitis B virus, Human ImmunodeficiencyVirus
(HIV/HTLV-III/LAV) or other infectious agents are
absent, all human blood products should be
considered potentially infectious. Handling should be in
accordance with the procedures defined by an
appropriate National biohazard safety guideline or
regulation, where it exists (for example USA Center for
Disease Control/National Institute of Health manual
Biosafety in Microbiological and Biomedical
Laboratories', 1984).
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Specimen collection and preservation
Note: samplemedium
In order to provide the appropriate assay blanks, the
sample medium (solution in which the sample is
collected, preserved, etc) must be brought to a
comparable weight or volume dilution as in the
samples to be run. For example, if plasma collected in
the special evacuated tube is being run, glass-distilled
deionized water (the volume of blood it will draw)
should be added to one of these evacuated tubes to
provide a comparable concentration for the blank. The
control plasma (vial 9) provided in the kit for reference
has been prepared with the same sample medium as
contained in the special evacuated tubes. Therefore, a
blank as prepared above would serve as background
for the control plasma. If samples are run together in
the assay that have different sample media, blanks
must be run for each medium. If further dilution of a
prepared sample is required, an equivalent dilution of
the sample medium must be provided to be used as
the blank. Store prepared sample medium in
refrigerator at4- 10C prior to use.
Blood
Blood may be collected using special evacuated tubes
which can be obtained from Amersham (code
RPN.532). Alternatively, blood may be collected with a
syringe and transferred to a suitable tube, or the user
may prefer to use an evacuated tube of his own
preparation.
Warning: It is essential to follow the directions given
here exactly, otherwise specimen collection may
adversely affect assay results.
The evacuated tubes available from Amersham
contain an anticoagulant, EGTA, and an antioxidant,
glutathione. These substances are added to the tubes
in a solution (pH60-74) which contains 90mg/ml
EGTA and 60mg/ml glutathione. Twentymicrolitres of
this solution is needed for each ml of blood to be
collected. A standard evacuated tube containing
heparin can be used if the proper amount of
glutathione is used as stated above. However, other
anticoagulants (EDTA, citrate, oxalate) or antioxidants
(sodium metabisulphite, ascorbic acid, etc) are not
recommended.
Instruction for drawing blood and preparation of
plasma
The hazards of viral hepatitis in laboratories have been
recently reviewed171. Operators should consult this
review or other sources formore specific details of
proper methods of handling and disposing of
specimens, and personal safety.
For convenience a step by step collection and
preparation procedure follows:
1) After the patient has remained in the supine position
in nonstimulating surroundings for at least 30 minutes,
draw blood. Take care to avoid haemolysis.
2) Invert the tube several times to mix blood with
preservatives. Do not shake.
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3) Immediately place the tube in an ice bath.
4) Centrifuge in a refrigerated centrifuge as soon as
possible. (If a refrigerated centrifuge is not available,
centrifuge cups or carriers should be pre-chilled).
5) Immediately separate the plasma using a
disposable pipette. Take care to avoid the transfer of
any cells. Place the clear plasma in a suitable container,
and freeze in an upright position. (If the assay is to be
completed the same day the specimen may be stored
in a refrigerator). Frozen plasma is stable for at least
three monthswhen stored in a tightly closed container
at a temperature below -20C.
Caution: In some patients, the venipuncture event may
cause plasma catecholamines to rise temporarily, even
though the patients are not noticeably nervous or
upset. When such responses to venipuncture are
anticipated, we recommend the use of an intracath or
large bore intermittent infusion set which is placed in
the cubital vein or other convenient vein, flushed with a
heparin solution (10U/ml), and occluded (heparin
lock). When the line for blood drawing is secured, the
patient is left recumbent in nonstimulating
surroundings for 30 minutes.
At the end of this period, the heparin is flushed from
the infusion set by withdrawing a small amount of
blood (0-5ml) with a syringe and discarding it. Then,
blood is withdrawn. With the needle removed from the
syringe, the blood is immediately transferred to a tube
containing the additives as described above.
Alternatively, the blood could be withdrawn from the
infusion set through a needle holder directly into an
evacuated tube.
Cerebrospinal fluid
Cerebrospinal fluid (CSF) may be added directly in the
incubation mixture for the catecholamine analysis.
However, it is recommended that immediately upon
collection, 20ul of the EGTA/reduced glutathione
solution described in the section on blood collection
should be added to each ml of CSF collected. Samples
should be stored frozen in a tightly closed container at
a temperature below -20C.
Urine
Twelve hour urine samples should be collected in a
2 litre plastic bottle with screw cap (or other suitable
bottle) containing 5ml of 6M hydrochloric acid (HCI).
The total volume should be accurately measured. If a
random urine is collected, the pH should be
immediately lowered to between 1 and 2 with
concentrated HCI. Remove a suitable aliquot (5ml)
and add 20gl of the EGTA/reduced glutathione
solution described previously per ml of urine. Store the
urine aliquot containing glutathione below
- 20C until
assayed. Due to the sensitivity of the assay, most urine
specimens will require accurate dilution prior to use.
The actual dilution used will depend on the particular
specimen; typical dilutionsmay be in the range of
1:100. An allowance for the dilution of the urine
(including the volume of the added HCI) should be
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made when calculating the final concentrations of
catecholamines.
Tissues
Tissue should be frozen in liquid nitrogen or on dry ice
immediately upon excision. The tissue should be
homogenized in freshly prepared appropriate acid (for
example 10ml of cold 04N perchloric acid/gram wet
weight of tissue) containing 5mM reduced glutathione




supernatant should be removed and stored frozen in a
tightly closed vial or tube. The application of other
perchloric acid concentrations or other acids or agents
for
'deproteination'
may also be successful. However, it
is imperative that a
'tissue-free'
sample, which will serve
as a blank, be treated under the same conditions, that
is, identical volumes of buffer or acid, centrifugation,
dilution volumes, etc. as the tissue. Due to the high
catecholamine concentrations in many tissues and to
the sensitivity of this assay, it will be necessary, in most
instances, to dilute the protein-free supernatant with
glass distilled deionized water. Typical dilutions for brain
tissue may be in the range of 1 :20, heart tissue 1 :50
and tumour 1 :200 or higher.
Caution:When adding acidic
'protein-free'
supernatant of tissue homogenate to an incubation
mixture, be certain that the acidity of that addition will
not exceed the buffer capacity of the mixture and
denature the enzyme.
Equipment and supplies required
In addition to the reagents supplied with this kit, the
following equipment and supplies are required. The
listing of specific products in the following list is not an
endorsement of that product, but merely lists products
which are available commercially and were used
during the development of this assay system.
Materials and equipment
The following materials and equipment are required:
Test tubes- 13x 100mm and 16x 125mm (total
catecholamines assay only) glass disposable tubes.
Test tube racks for above tubes.
Stoppers, Neoprene, Size 0 to 1 .
Pipettes-disposable tip pipettes capable of aliquotting
10,40and50ul.
Incubation or constant temperature water bath with
shaking action capable of holding water temperature
at37C2C.
Centrifuge -clinical type ambient temperature to be
used with above test tube sizes capable of 1000xg with
swinging bucket head.
Vortex mixer,
Thin layer plates- Silica Gel GF 250 micron thickness;
10x20cm plates prescored to eight 2 5x 10cm plates
(Analtech Uniplate, Analtech, 75 Blue Hen Drive,
PO Box 7558, Newark, DE1971 1).
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Standard laboratory glassware.
Container for dry ice-alcohol,
Dry ice.
Spotting pipettes or capillaries for manual application
of extracted catecholamine derivatives onto thin layer
plates.
The application of the extracted catecholamines onto
thin layer plates can be facilitated with the use of an
automatic spotting device (TLC Multispotter,
Analytical Instrumentation Specialties Supplier. AIS,
PO Box 596, Libertyville, IL 60048) with 16 syringe
cradle and blower/baffle attachment. Syringes that
should be used with the spotter are AIS 250 microliter.
Specify To be used with Multispotter,
CAT-A-KIT
assay system'.
Developing chamber for development of thin layer
plates.
An ultraviolet light source, 254nm wavelength.
Scintillation vials.
Adjustable constant volume dispenser for solvents and
solutions.
Shaker evaporator (total catecholamines assay only).
0-Scintillation counter.
Scintillant-a concentrated toluene solution of PPO
and POPOP for example, Spectrafluor, available from
Amersham Corporation, code 190650 for 500ml and
code 190651 for 1 litre, and Liquifluor, New England
Nuclear.
Solvents and solutions
Toluene analytical reagent (A.R.) grade.
Isoamyl alcohol, A.R. grade.
Spectrafluor, Amersham Corporation, Arlington
Heights, IL. (see scintillant, materials and equipment)
Benzene, A.R. grade*.
Tertiary amyl alcohol, A.R. grade.
Methylamine solution (40% in water).
0-1M acetic acid.
Ethyl alcohol, absolute.
005M Ammonium hydroxide (make fresh regularly).
Glass-distilled, deionized water.
Solventmixtures to be prepared
1) Toluene/isoamyl alcohol (3:2) (v/v).
2) Tertiary amyl alcohol/benzeneVmethylamine
solution (6:2:3) (v/v/v).
3) Toluene/Spectrafluor (1000:50) (v/v).
4) Toluene/isoamyl alcohol/Spectrafluor (700:300:50)
(v/v/v).
If benzene is not available, a solvent system consisting ol




1) Thaw and examine samples. If they are not clear,
centrifuge to free the sample of particulate matter.
Caution: Presence of haemolysis, cloudiness or
solidmatter in specimensmay give Invalid results.
Dilute those samples which require dilution with
distilled water. All distilledwater used here and in
subsequent steps of the assaymust be glass
distilled deionizedwater. If sample dilution is
required, an equivalent dilution of the sample medium
must be assayed as the blank.
2) Determine the number of tubes (13x 100mm)
required from table 1 . Number each tube and place in
an icewater bath.
3) Aliquot two (2) 50ul portions of each sample (B in
table 1) into the appropriate tubes (when performed in
duplicate a total of 4 tubes per sample will result).
Include vial 9 as a sample to assess the performance of
the kit. Where samples are run using a different media,
separate blanks must be run for each medium.
4) Dilute a portion of vial 2 1 : 10,000 with distilled water.
Add 10gl to the first aliquot of each sample (C in table
1). Similarly dilute a portion of the vial 1 1:10,000.
Store in ice bath. Add 1 0ul of the diluted standard
solution to the second aliquot of each sample (D in
table 1).
5) Prepare a reagent mixture in a suitable disposable
tube with the following components added in the











Multiply the volume of each reagent by the number of
tubes determined in step 2 plus a two tube excess for
every run. Vortex the mixture lightly before adding vial
5, COMT, and lightly again when the reagent mixture is
complete. Add 40ul of the reagent mixture (E in table
1) to all tubes last.
6) Mix lightly Centrifuge briefly (300xg for
30 seconds). Incubate all tubes at 37C for 1 hour in a
shaking water bath.
7) After incubation, return the tubes to the ice bath.
Add 50gl of vial 6 to each tube and mix vigorously.
(The stopping solution consists of each of the products
of the enzymatic reaction normetanephrine,
metanephrine and methoxytyramine at a
concentration of 4mM, to serve as carriers for the
radiolabelled reaction products).
Number a second set of 13 x 100mm test tubes.
(16x1 25mm tubes required if only total
catecholamines are to be determined).
16
8) Add 1 0Ogl of 0' 1 M acetic acid to each of the second
set of numbered test tubes.
9) Add 2ml of toluene/isoamyl alcohol (3:2 v/v) to the
incubation tubes, mix vigorously and centrifuge
(2 minutes at 800xg; subsequent centrifugations
should be performed in the same manner). Two distinct
layers should result. Quick freeze (15 seconds) each
tube in a drv
ice-alcohol*
bath.
10) Remove tube from the bath, blot outside of tube to
prevent dripping of alcohol, and decant the upper
organic phase into the corresponding tube containing
the acetic acid solution prepared in step 8. Discard
lower aqueous phase.
11) Mix vigorously, centrifuge and freeze as in step 9.
Aspirate off the upper organic phase and discard.
Ethanol. methanol or acetonemay be used in the dry ice-alcohol bath.
12) Thaw the aqueous acetic acid phase, add 1ml
toluene/isoamyl alcohol (3:2), mix vigorously,
centrifuge as above, quick freeze, aspirate and discard
the upper organic phase.
For total catecholamines assay go to page 20, for
completion of differential determinationproceed
to step 13.
13) Add 100-150pl of absolute ethanol to the thawed
acetic acid from step 1 2 to facilitate evaporation. Mix
until a clear solution results. Centrifuge at 800xg for
1 minute.
14) Prior to sporting, scribe channels on the thin layer
plate for desired number of samples. Number each
lane omitting outer lanes (see figure 3). Apply all of the
acetic acid/ethanol solution from step 13 1-5-2-0cm
from the bottom of the scribed thin layer plate:
(prescored plates need not be separated until step 17).
Table 1. Quantity of each reagent required per tube
A B C D E






Blank 2 50yl _ 10ul 40pl
Sample(s) 2 50ul 10ul
- 40ul
Sample(s)
+ standard 2 - 50ul 10ul 40ul
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The acetic acid/ethanol solution should preferably be
applied as a single spot using an automatic TLC
spotter. Alternatively, it may be applied manuallywith a
capillary, syringe or spotting pipette; in this case, the
sample should be streaked on the plate. Keep the band
or spot as narrow or small as possible to achieve the
best resolution. Awarm air stream is recommended.
15) Place the plate(s) in a paper-lined TLC developing
tank. Make certain that the solvent is at least 1cm
below the spots. Develop the TLC plates with a solvent
consisting of tertiary amyl alcohol/benzene**/
methylamine solution (6:2:3, v/v/v). Prepare solvent
immediately prior to use to obtain best separation.
Permit the solvent tomigrate to the top of the plate.
More than one plate may be developed in the same
tank at one time.
16) Remove the plate(s) from the tank and dry
thoroughly; discard the developing solvent. Visualize
the zones under the 254nm ultraviolet light. The top
zone contains 3-methoxytyramine; themiddle zone
contains metanephrine; the bottom zone contains
normetanephrine (see figure 3). Outline the zones in
the silica gel with the tip of a sharp object without
disturbing the zones.
17) Assemble in appropriate quantity three sets of
scintillation vials; one each for the adrenaline,
noradrenaline and dopamine assay. Carefully separate
the sections of the TLC plate at the prescored lines and
carefully scrape off the silica gel from each zone into a
correspondingly numbered scintillation vial. Each set of
the scintillation vials should now contain the silica
scraping for set 1) 3-methoxyryramine; set 2)
metanephrine, and set 3) normetanephrine,
respectively.
From this point on the assay for dopamine differs from
that of adrenaline and noradrenaline. Since the
procedure for the assay of adrenaline and
noradrenaline from the silica gel scrapings containing
the [3H] metanephrine and [3H] normetanephrine
utilizes the same steps and conditions, the assay of
these two sets of samples may be carried out
simultaneously. A separate section describing each
assay is detailed to prevent any confusion in the
processing of the isolated labelled derivatives.
Dopamine assay
18) To the scintillation vials containing silica gel from
the top zone, add 1ml of 0-05M ammonium hydroxide
to each vial to elute the methoxytyramine from the
silica gel. Mix vigorously.
19) Add 10ml of toluene/isoamyl alcohol/Spectrafluor
(700:300:50, v/v/v) to each vial, cap the vials, and
shake vigorously.
20) Dark control the vials and count in a liquid
scintillation counter. These vials contain radioactivity
from dopamine.
"II benzene Is not available a solvent system consisting ol









Rgure 3 Application of
[3H]-methoxycatecholamines to silica gel thin layer and
chromatographic separation.
Thin laver oiate f20 x 10cm) illustrating separation of
[3H]-methoxycatecholamines from 14 samples which were
srtt* s m aneously b^TLC
MU|,iSpotter. Note that the outside lane on each 20x
10cm PteteCprescored to
eiSt?5x^0cm terles) tenot used due to frequent
variations in uniformity of silica gel layer in
these edges.




21) To the scintillation vials containing the silica gel
from the middle zone (metanephrine) add 1ml of
0-05M ammonium hydroxide to each vial to elute the
amine from the silica gel. Mix vigorously (vortex or
equivalent).
22) To initiate the periodate oxidation step add 50gl of
vial 7 to each vial at timed intervals and mix vigorously.
Periodically shake the vials during the reaction.
23) Fiveminutes after the addition of periodate to the
first vial in step 22 above, add 50pl of vial 8 to each vial
maintaining the order and time interval established in
step 22.
24) Add 1 ml of
0- 1 M acetic acid to each vial and mix.
With adequate ventilation, add 10ml of
loluene/Spectrafluor (1000:50 v/v) to each scintillation
vial.
25) Cap the vials and shake vigorously. Dark control
the vials and count in a liquid scintillation counter.
These vials contain the radioactivity from adrenaline.
Noradrenaline assay
26) To the scintillation vials containing the silica gel
from the bottom zone (normetanephrine) add 1ml of
0-05M ammonium hydroxide to elute the amine from
the silica gel. Mix vigorously (vortex or equivalent).
27) To initiate the periodate oxidation step add 50gl of
vial 7 to each vial at timed intervals and mix vigorously.
Periodically shake vials during the reaction.
28) Five minutes after the addition of periodate to the
first vial in step 27 above, add 50gl of vial 8 to each vial
maintaining the order and time interval established in
step 27.
29) Add 1ml of
0- 1 M acetic acid to each vial and mix.
With adequate ventilation, add 10ml of toluene/
Spectrafluor (1000:50 v/v) to each scintillation
vial.
30) Cap the vials and shake vigorously. Dark control
the vials and count in a liquid scintillation counter.




If the differential determination of the three
catecholamines is not desired, total catecholamines
(noradrenaline and adrenaline) can be determined.
31) For the total catecholamines assay, the procedure
is identical to that used for the differential assay (steps 1
through 1 2). The remainder of the procedure follows
here.
32) Dry the acetic acid solution from step 1 2 under a
stream of air or under reduced pressure.
33) Add 1ml of 0-05M ammonium hydroxide to the
dried residue (which may not be visible) and vortex
vigorously.
34) To initiate the periodate oxidation step add 50gl of
vial 7 to each tube at timed intervals and mix
vigorously. Periodically shake tube rack during
reaction.
35) Fiveminutes after the addition of the periodate to
the first tube in step 34 above, add 50ul of vial 8 to
each tube.
36) Add 1ml 0 1M acetic acid to each tube and mix.
With adequate ventilation, add 10ml of
toluene/Spectrafluor (1000:50 v/v) to each tube,
stopper and shake vigorously for 30 seconds.
Centrifuge for 2 minutes at 800xg and freeze in a dry
ice alcohol bath for approximately 1 minute.
37) Decant the upper organic phase from each tube
into a separate scintillation vial containing 2ml of
0' 1M
acetic acid. Cap the vials and shake each vigorously.
Dark control the vials and count in a liquid scintillation
counter. Discard the lower (aqueous) phase remaining
in the test tubes.
38) The vials at this point contain the radioactivity from
noradrenaline plus adrenaline (since dopamine is not
susceptible to the periodate oxidation, it does not
contribute to the radioactivity in these samples. Its
presence in the standard solution does not affect the
results). Please note section on typical data and
calculations for the total catecholamines assay. The
picograms of standard in the calculation equations is
the sum of noradrenaline plus adrenaline.
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Procedural notes
Order of addition of reagents
The order of addition indicated in steps 3 through 5 is
recommended. Particular care should be taken to
vortex the reagent mixture after the addition of vial 4,
(step 5) which is strongly acid, so as not to layer the
enzyme onto the acid and cause extensive
denaturation.
Standard
The catecholamines assay has been shown to be linear
to 3000pg per assay sample for noradrenaline (NA),
adrenaline (A), and dopamine (DA), when these
standards were added to samples from a plasma pool
at 0-5 log intervals.
Dilution of standards and samples
The dilution specified in step 4 produces a standard
with a content of 100pg of each catecholamine in the
10ul aliquot added to the incubation mixture. Although
it is recommended that 100pg be used as the
standard, the concentration of the standard may be
adjusted to be compatible with the quantity of
catecholamines anticipated in the sample.
Further dilution of the sample with diluted vial 2 or
distilled water would be more appropriate than
increasing the standards. If any sample appears to
contain more than 3000pg of any catecholamine it
should be diluted appropriatelywith the diluted vial 2
(step 4) and repeated. In the event that the
catecholamine concentration in the sample is quite
high, the relative contribution of the standard to the
total counts may be greatly decreased from that in
other samples or may not even be detectable,
Mixing
Since this assay is dependent at several steps upon
partitioning of labelled product from one phase to
another, the action should be severe enough to ensure
thorough mixing of the phases. The best mixing is
achieved by several brief vortexings with a pause
between them. Ideally total time is approximately
15 seconds.
Recommended stopping points
Sometimes the operator may not be able to complete
the differential assay in a single working session. Steps
in the procedure where the assay may be terminated
for the session are a) following step 1 2, at which time
the catecholamines have been extracted and are in
acetic acid (stopper tubes and store below -20C),
and b) after step 1 6 or 1 7, the TLC separation of
catecholamines. If the interval at b) will be longer than
overnight, it is recommended that the TLC plates be
placed in a desiccator and frozen.
Radioactivity counting
It is not necessary to separately count instrument
background. The background is part of the assay
blank and is therefore subtracted in the calculations.
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The user should count each vial for a period of time
sufficient to achieve good counting statistics.
Amersham recommend a counting time of 10
minutes. Under exceptional circumstances a counting
time of 4 minutes will provide acceptable results. In
general, Amersham urges users to count as long as
possible to reduce this source of error in their final
results.
Inhibition ofO-methylatlon
Some plasma samples may appear to inhibit the
O-methylation of the catecholamines as evidenced by
a low increment of radioactivity attributable to the
added standard (CPM/picogram standard). If an error
in delivering the standard can be ruled out, that sample
should be diluted (that is 1 :3 or 1 :10) with distilled water.
Limitations of use
Catecholamine levels can be falsely elevated if the
samples are not collected as instructed (see page 10).
Please take particular care when collecting these
samples to allow an accurate representation of
catecholamine levels (see pages 1 1 , 12 and 15).
Some medications have a direct or indirect
interference on the catecholamine assay. Please refer
to appendices I and II for information.
Tissuemeasurements of catecholamines require
extreme care as it pertains to batch sample extraction
and preparation of this extraction for radioenzymatlc
assay. Please note the section discussing tissue
preparation on page 13.
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Typical data and calculations
A. Differential determination
The data summarized in table II provides an example
for the calculation of catecholamines content in
plasma.





1 Blank 31 28 184
2 Blank 36 28 181
3 50ul Plasma #1 402 238 275
4 50gl Plasma #1 449 254 329
5 50gl Plasma #1+Std 3259 3397 2964














Catecholamine concentration (pg/ml) =
CPM sample-CPM blank pg standard
CPM (sample+std)-CPM sample



















**Note: If dilution of sample is required, be sure to
correct for dilution factor.
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B. Total catecholamines
The data summarized in table III provides an example
for the calculation of total NA and A in the total
catecholamines assay.







3 50gl Plasma #1
4 50gl Plasma #1
5 50gl Plasma #1+Std







All standards are 200 picograms (sum of













CPM sample-CPM blank pg
standard*
CPM (sample +std)-CPM sample ml sample
vol.'










The radioactivity produced by the standards in the
results listed (page 23) was obtained utilizing a stock
CAT-A-KIT1". Radioactivity in the standards will vary
with the specific activity of the substrate [3H]-SAM and
also because of variations in theO-methylating
efficiencies of the three substrates, efficiency of
extraction, and variations in scintillation counting
efficiency with the various solvents. The extent of the
labelling in the three standards will not be equal but
they should approximate the proportions or ratios
indicated in the typical data.
Use of standards
This assay is dependent upon the efficiency of the
COMT enzyme to transfer the labelled methyl group
from [3H]-SAM to the catecholamines. Therefore, it is
necessary to add a standard to a second aliquot of the
sample to accurately assess the methylating efficiency.
EGTA has been added to the incubationmixture to
increase the efficiency of themethylation in the
presence of plasma.
Interfering substances
Although the extraction steps, togetherwith the thin
layer chromatographic separation and periodate
oxidation, provide specificity for the catecholamines
assayed, catechol-containing compoundsmay
interfere. Thedrugs listed in appendix I and/or their
metabolitesmay give a positive response in this assay.
This may bemost noticeable in the total
catecholamines assay. Common interfering
substances are a-methyldopamine and
a-methylnoradrenalinewhich are metabolites of
a-methyldopa*(Aldomet*
Merck), and isoproterenol.
In addition, the drugs listed in appendix II may alter
endogenous catecholamine levels.
Caution: Radiopaque materials (X-ray contrast media)
which contain iodinemay interfere with the enzymatic
derivatization of the catecholamines. Specimens for
catecholamine analysis should not be drawn until such
materials have been cleared from the circulation.
Crossover of catecholamine assays
The extent of crossover of one catecholamine into the
assay of a second has been determined by the addition
of a single catecholamine standard (as obtained
commerciallywithout further attempts at purification)
to a plasma-containing incubate.
Crossover on the basis of total radioactivity produced
by the standard is summarized as follows:
a-methyldopa ilselt does not interfere
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Each mean is the average of 6 determinations.
'Sampleswith elevated levels ol dopamine could show higher crossover
Into adrenaline"'.
Sensitivity
The data summarized in the section on sample
calculations provides an indication of the sensitivity of
the differential assay. The radioactivity in the respective
blanks Is equivalent to approximately 1 2pg NA,
0 9pg A and
7- 1 pg DA. Thus, the realised sensitivity of
the assay (at twice the radioactivity equivalents in the
blank) is then NA, 2 4pg; A, 1 8pg and DA, 142pg per
50gl sample assay, Expected sensitivity will range from




Asmeasured in groups of four for additions of
standards at 0 5 log intervals from a blank (Opg) to
3000pg the average coefficient of variation was
NA, 42%; A, 36% and DA, 4-6%.
Variation between runs
Asmeasured 35 times over a period of onemonth, the
coefficient of variation for between assay performance
of a human plasma sample spiked with three
catecholamineswere: NA, 7-5%, A, 10% and
DA, 1 2-6%. The individual values in these experiments
were NA, 708pg/ml 53; A, 509pg/ml 47;
DA, 444pg/ml 56 (mean S.D.). A second human
plasma spiked with DA only was measured 16 times
over 7 weeks resulted in coefficients of variation for
NA, 7 8%; A, 13 5% and DA, 1 1 8%. Individual values
for these experimentswere NA, 191 pg/ml 15;
A, 53pg/ml 7 and DA, 228pg/ml 27. Relatively high
coefficients of variation in catecholamine levels
determined by thismethodology may be observed
when these levels approach the limit of sensitivity of the
assay, for example, DA in the plasma of normal
patients has been discussed by Michaels'9'.
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CAT-A-KIT
assay system
(Catecholamines [3H] radioenzymatic assay]
codeTRK.895
Contents
Each pack contains the following components:
1 Vial (vial 1 ) containing standard catecholamines; 100ug per ml
each ot i noradrenaline, i adrenaline and dopamine in acidic
glutathione solution
1 Vial (vial 2) containing stabilizing solution, acidic glutathione
solution
1 Vial (vial 3) containing assay buffer, a ready to use solution ol Tris
buffer pH8 5 containing ethylene
glycol- bis (fl-aminoethyl ether)
N, N -tetraacetlc acid (EGTA) and MgCI,
2 Vials (vial 4) ol S-adenosyl-i-ImetfiyPH]methionine, 925MBq;
250uCi in HCIethanol 9:1 . pH2 1 .
2 Vials (vial 5) of enzyme: a ready to use solution ol rat liver
catechol-O-methyltransferase in Tris buffer containing glutathione,
benzylhydroxyamine hydrochloride and dithiothreitol.
1 Vial (vial 6) ol a ready to use solution ol stopping solution: 4mM
each ol normetanephrine, metanephrine and methoxytyramine In
borate buffer pHl 1 containing EDTA.
2 Vials (vial 7) ol a ready to use solution ol 4%w/v sodium
metaperiodate
2 Vials (vial 6) ot a ready to use solution of 1 0% v/v glycerol.




Each pack contains sufficient material for 90 assay tubes
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The expiry date is stated on the package and will normallybe at
least lourweeks from the date ol despatch.
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He entire procedure from
I
start o/ extraction to the
final result is under 30
minutes.
Continuously elevated levels ol
norepinephrine and dopamine
are indications ol certain
neurological disorders and
adrenal medulla tumors. It has
become prudent to monitor
catecholamine levels in certain
hypertensive patients since
hypertension may result irom
adrenal medulla tumors. These
tumorsmay be treatable if
diagnosed early in their formation.
Various technologies have been
utilized tomeasure plasma
catecholamine levels. Most have




chemical detection has proved to
be a cost-effective and reliable
means for performing these
determinations.
A drawback of early electro
chemical determinations of
catecholamineswas the
interference by uric acid. Uric acid
co-elutedwith norepinephrine in
many chromatographic systems,
and it was sometimes impossible
to separate them. Another
problemwith detection of the
catecholamineswas the laborious
sample preparation required to





provides a means of
electrochem-
ically separating interfering
substances, such as uric acid, from
the components of interest.
ESA hasmodified the procedure of
Anton and Sayre so that the entire
analysis from start of extraction to
final result is under 30 minutes.
Figure 1.






Because of the unique coulometric
design of the Coulochem, virtually
100% of each compound is
oxidized or reduced by each
electrode. By selective choice of
potentials, one or more
compoundsmay be removed at
upstream electrodes, leaving only
the specific compounds of interest




ascribes the behavior of






dopamine with the corresponding
curve for uric acid.
Voltage
The approximate potentials for this
analysiswere derived from a
current-voltage curve determined
by experimentation. To produce a
C-V curve, a constant mass is
injected while the applied
potential is varied. The curve
(Figure 2) describes the behavior
of a compound of interest to
oxidation and/or reduction
potentials.
The optimum potentials for the
three catecholamines of interest
are: -0.26 V for reduction and
+0.35 Vfor oxidation. However, to
eliminate the effects of uric acid,
the following oxidation and
reduction potentials were used:
Conditioning Cell = + 0.4 V





With these potentials, the
compounds are fully oxidized at
the conditioning cell. At the first
analytical electrode (T, ), the
catecholamines are non-reacting
but a screening reduction takes
place. At the second analytical
cell (T2) reduction of the
catecholamines is accomplished.
Figure 3 shows a chromatogram of
an aqueous standard containing 1
ng each of norepinephrine,
epinephrine, and dopamine. 1 ng of
DHBA (dihydroxybenzylamine)was
added prior to the extraction as
the internal standard. The
extraction proceeded to a 68%
recovery of DHBA The
chromatogram is complete in less
than 8 minutes.
Figure 3.
Chromatogram of an aqueous




















Chromatogram of aplasma sample.
Figure 4 is a chromatogram of a
plasma sample to which 1 ng of
DHBAwas added as the internal
standard.
The mobile phase consisted of 6.9
g/L monobasic sodium phosphate
(NAH2PO4), 250 mg/L heptane
sulfonic acid, and 80 mg/L EDTA
The pH was adjusted to 3.6with
phosphoric acid and injected into
the Model 5700 Solvent Delivery
System.
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Hematoporphyrin Derivative Fluorescence:
Photographic Techniques for the Localization
of Malignant Tissue
Raymond J. Lanzafame, md, Jeffrey R. Blackman, bs, David W. Rogers, bs,
John O. Nairn, ms, Ralph P. Pennino, md, and J. Raymond Hinshaw, md, dphh,
FACS
Department of Surgery (R.J.L, D.W.R., J.O.N., R.P.P., J.R.H.) and Department ofMedical
Illustration (J.R.B.), Rochester General Hospital, University of Rochester School of
Medicine, Rochester, New York
Three simple methods for the detection of malignancy by the photography of
hematoporphyrin derivative (HPD) fluorescence are presented. Two methods
employ a single lens reflex camera with macrolens and Kodak high-speed Ekta-
chrome (EL 400) film. Both employ a Corning Glass #3482 filter as a barrier on
the lens. In method I, a single Kodak Wratten #39 filter is placed over a fluorescent
"black
light"
source (two General Electric F20T12BL 20-W bulbs). In method II,
twin electronic flash units (5,500 BCPS unfiltered) with a double thickness of
Kodak Wratten #39 filter over them provide the light of excitation. Method III
employs an adapted Polaroid SLR 680E Sun camera with two electronic flash
units (5,500 BCPS, total unfiltered) rigged with a slave trigger. A Corning Glass
#3482 filter is placed on the lens to act as a barrier, and two filters of Kodak
Wratten #39 glass are placed on each flash unit. Photographs are taken in a
darkened room.
Key words: tumor localization, 35-mm photography, instant photography
INTRODUCTION
The ability to detect tumors and define their extent
is of practical importance to the clinician. The porphyrins
have attracted specific interest as tumor markers, since
Policard observed the reddish fluorescence of endoge
nous porphyrins in human and animal tumors in 1924.
In 1942 Figge and Clark reported a photographic
method to record this fluorescence. Peck et al [1955]
used this method to demonstrate the biliary tree, lymph
nodes, and neoplastic tissue in both humans and animals.
Henderson et al [1980] used a similar method for the
detection of hematoporphyrin diacetate. However, with
the exception of a modified technique reported by Benson
etal [1982], the photographic methodologies have fallen
from use in favor of the development of electrooptical
imaging technologies, including the use of image
inten-
sifiers [Balchum et al, 1983; Doiron et al, 1979; Hayata
et al, 1982a,b, 1983; King et al, 1983; Lin et al, 1984;
Profio et al, 1979, 1983; Auler and Banzer, 1942;
Dougherty et al, 1985].
Advances in photographic technology have again
made photographic methods practical for the detection of
malignancy. Two simple methods using 35-mm photog
raphy for the detection of tumors are described in this
article.
Work in our laboratory with instant imaging of
sodium fluorescein [Lanzafame et al, 1983] has provided
the expertise necessary for the development of a similar
methodology for the photography of HPD fluorescence.
An instant photographic method for the detection and
localization of tumors after injection of hematoporphyrin
derivatives is also presented in this article.
MATERIALS AND METHODS
The methods were developed and tested in both in
vitro and in vivo systems. The hematoporphyrin deriva
tives HPD and HPD2 (Photofrin and Photofrin 2; Pho-
Accepted for publication January 21, 1986.
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tofrin Medical, Cheektowaga, NY) were prepared in pH
7.35 Dulbecco's phosphate-buffered saline (GIBCO,
Grand Island, NY) at concentrations of 250, 50, 25, 10,
5, 2.5, and 1.25 pg/ml and 750, 500, 250, 100, 75, 50,
25, and 5 ng/ml and placed on 2-inch filter paper discs.
All photographic exposures were made under similar
conditions and with the room darkened.
The R3230AC mammary tumor was transplanted
by trocar and grown to a size of 2.5 cm in 150-gm female
Fisher 344 rats. The animals were given intravenous
injections of HPD or HPD2 at doses of 15, 10, 5, or 3
mg/kg from 24 to 96 hours prior to photography. Each
tumor was photographed in situ and after having been
removed and bisected. All photographs were taken under
similar conditions in a darkened room. The photographic
methods are described separately.
Method I: Black-Light Photography
A 35-mm single-lens reflex camera is fitted with a
100-mm macrolens, and the aperture is set at f4. Photo
graphs are taken at one-third life size. An orange Corning
Glass #3482 sharp cut-off filter is placed over the lens to
serve as a barrier filter. The excitation light source con
sists of two fluorescent "black
light"
bulbs (General
Electric F20T12BL, 20 W) over which an opaque cover
with a 3-inch square window is created and covered with
a blue Kodak Wratten #39 filter. This apparatus is shown
in Figure 1. Kodak high-speed Ektachrome film EL400
(ASA 400) is used. All exposures are made in a darkened
room with the light source 8.5 inches from the specimen.
An exposure time of 30 seconds is used.
Method II: Electronic Flash Photography
Two electronic flash units are mounted on a bracket
system and angled at
45
relative to the subject. The total
unfiltered flash output is approximately 5,500 BCPS.
Each flash is fitted with a double thickness (ie, two
329
filters) of Kodak Wratten #39 filters. This arrangement
provides a light intensity of 100 foot-candles at the spec
imen surface (an approximate guide number of 4). The
same reflex camera, barrier filter, film, and aperture are
used as described in method I. All exposures are made in
a darkened room. This apparatus is demonstrated in Fig
ure 2.
Method III: Instant Photography
The camera system used is demonstrated in Figure
3 . A Polaroid SLR 680E Sun camera was mounted to a
bracket with two electronic flash units. One of the flash
units is attached to a simple slave trigger. The flash units
are positioned at a 45 angle relative to the subject, and
their combined, unfiltered output is approximately 5,500
BCPS. Each flash unit is fitted with a double thickness
(ie, two filters) of Kodak Wratten #39 blue filter. This
Fig. 2. Assembled flash and bracket system for fluorescence photog
raphy. A, Kodak Wratten #39 exciter filters (two placed on each flash
unit as a sandwich); B, Corning Glass #3482 filter as a barrier filter.
Fig. 1. Excitation light box for black-light photography.
Fig. 3. Camera apparatus for method III. A, Polaroid SLR 680E
camera; B, Kodak Wratten #39 filters (two thicknesses each); C,
Corning #3482 glass filter; D, slave trigger; and E, black tape cover
ing camera electronic eye.
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provides 100 foot-candles of light intensity at the speci
men surface and an approximate guide number of 4. The
camera lens is fitted with an orange Corning Glass #3482
filter. The built-in camera flash unit is switched off, and
the camera's electronic eye is covered with black tape.
These maneuvers cause the aperture to open fully (f8)
and the shutter to remain open for 5 seconds. Therefore,
all photographs are taken in a darkened room. The pho
tographer depresses the camera shutter and then man
ually triggers the electronic flash on the left, which in
turn fires the second flash unit via the slave trigger. The
camera is fitted with standard Polaroid High Speed Color
Land Film (ASA 600). The photographs are immedi
ately available for diagnostic purposes if desired.
RESULTS
The black-light and electronic flash methods pro
duce nearly identical photographic renditions. At the
appropriate concentrations, HPD (HPD2) produces a
brilliant red fluorescence as compared to the background
(Fig. 4). The depiction of the fluorescence phenomenon
is of high contrast in contradistinction to the method of
Benson et al [1982] (Fig. 5).
The in vitro sensitivities of method I and method II
are depicted in Figure 6A and are compared to the Ben
son technique (Fig. 6B). The threshold of detection with
both method I and method II is 50 ng/ml for both HPD
and HPD2. There is a rapid decline in the intensity of the
fluorescence obtained at concentrations below 1.25 jxgl
ml. The Benson technique [Benson et al, 1982] is much
less sensitive, with a 5 pg/ml threshold of detection in
vitro. There was a similar insensitivity of the Benson
method in the R3230AC tumor system, with barely dis
cernible fluorescence noted in tumors taken from animals
receiving 3 mg/kg or less ofHPD (HPD2) intravenously.
Both photographic methods detect tumor by dem
onstrating brilliant red tumor fluorescence following in
travenous injection of HPD or HPD2 at all doses tested.
This is demonstrated in Figure 4.
The Polaroid images produced by method III are
equivalent to the images obtained with the 35-mm meth
ods both in vitro and in vivo with the R3230AC mam
mary tumor models.
Tumor fluorescence as depicted by method III is
demonstrated in Figure 7 and is similar to the fluores
cence demonstrated in the in vitro studies. Each tumor
fluoresces brightly after intravenous injection of HPD
(HPD2). As is shown in Figure 7B, the fluorochromes
are retained in the tumor for up to 96 hours following
injection. Note that each sample in Figure 7B is tumor
from a separate animal and that the animals received
various doses of HPD (HPD2) and were biopsied from
24 to 96 hours postintravenous injection of the drug.
DISCUSSION
The need for a simple, accurate method to detect
and document malignancy cannot be underrated. The
derivatives of hematoporphyrin are retained in neoplastic
tissue longer than in normal tissue, permitting both tumor
detection [Peck et al, 1955; Henderson et al, 1980; Ben
son et al, 1982; Balchum et al, 1983; Doiron et al, 1979;
Hayata et al, 1982a,b, 1983; King et al, 1983; Lin et al,
1984; Profio et al, 1979, 1983; Auler and Banzer, 1942;
Dougherty et al, 1985; van der Putten et al, 1983a,b;
Dougherty, 1984] and selective photoradiation therapy
(PRT) [Hayata et al, 1982a; Dougherty et al, 1985;
Dougherty, 1984] with these drugs. The observation of
tumor fluorescence when exposed to ultraviolet light
[Policard, 1924; Auler and Banzer, 1942] is the founda
tion for the use ofHPD and related compounds for tumor
detection.
The excitation and emission spectra for HPD are
shown in Figure 8 [Doiron et al, 1979]. These curves
were generated for HPD in solution. However, in vivo a
slight red shift is noted in both the absorption and emis
sion spectra of HPD. By using appropriate filters, it is
possible to provide a specific light of excitation, namely,
light with a peak wavelength of 390-410 nm, which
corresponds to the wavelengths at which HPD is most
strongly excited. Both the black light and xenon arc lamp
(electronic flash) are adequate sources of these wave
lengths.
Since the HPD fluorescence is very weak and peaks
at 630 and 690 nm, it is desirable to filter out unwanted
nonfluorescent wavelengths. This serves to enhance the
contrast and makes it necessary for the photographs to be
taken in a darkened room. It is necessary to allow some
extraneous light to reach the film to permit the definition
of anatomical structures. Were this not done, the resultant
image would be areas of red fluorescence on a stark
black background.
The transmission curves for the #3842 Corning
Glass filter and the Kodak Wratten #39 filter are shown
in Figure 9. It is readily appreciated that these filters are
quite suitable for the purpose of excitation of HPD and
for the filtering of virtually all but the resultant fluores
cence from reaching the photographic film. Preliminary
work with a single Kodak Wratten #39 filter over the
electronic flash (method II) produced an unacceptably
high amount of background illumination. It was deter
mined that the small window at 560 nm at a density of
3.0 was the cause (see Fig. 9B). Therefore, since densi
ties are additive, the addition of a second filter (ie, double
thickness) should reduce the amount of light transmitted
from the flash without affecting the main wavelengths of
excitation. This was borne out in further experiments and
is the basis for the double thickness of filter used in
method II and method III.
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Fig. 4. Tumor fluorescence after HPD injection. Both method I and
method II produce similar images.
Fig. 5. Tumor fluorescence as demonstrated by the technique of





Fig. 6. In-vitro sensitivity of photography of HPD on filter Daner A * ml- s -><;n ; i _, ^
Method I and method II images (note that method III produces equtV aT 19821
* ' ' 5 "^ B) Be"SOn teChniC1Ue&
alent images). 1, 3 Mg/ml; 2, 1.25 Mg/ml; 3, 750 ng/ml; 4. 500 ng/
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Both method I and method II provide accurate,
sensitive means of detecting HPD in malignant tissues
with an in vitro threshold of 50 ng/ml and bright fluores
cence at 1.25 pg/ml. Such concentrations are well within
the range of the 2-5 mg/kg doses of HPD (HPD2) used
clinically.
As noted by other investigators [Dougherty et al,
1985] , HPD2 causes slightly more intense tumor fluores
cence than HPD, but this difference is not significant.
When photographed in solution, HPD fluoresces slightly
more than HPD2.
The advantages of method II are that the system is
more compact and lighter and the exposure time is much
shorter. However, both methods I and II have the disad
vantage of requiring film processing for
the results to
become apparent. Therefore, neither method is useful as
a means of diagnosis, which would allow for PRT at the
same sitting. It is possible, however, to document the
.... . photographed at various intervals after HPD
injection and
Fig. 7. In vtvo photographs of
fluorescence after HPD inject.on
~
nfdtfe ent injected doses of drug.















Fig. 8. Excitation and emission spectra of hematoporphyrin deriva
tive. Adapted from Doiron DR et al [1979].
following local injection
or painting of lesions with these
compounds. Suspension ofHPD in formulations contain
ing azone and
N-methylpyrolidone have been shown ex
perimentally to
penetrate tissues more readily than HPD
alone [McCullough et al, 1983].
Photographic monitor
ing will allow refinement
of technique and may reduce
the frequency of adverse systemic
effects.
Future modifications and stronger light sources may
allow the endoscopist to localize and document disease
in situ without the need of image
intensification. Lastly,
method III provides a simple, instantaneous means of
documentation that the target tissue does indeed contain
drug prior to the initiation of PRT.
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Fig. 9. Transmission curves for Kodak Wratten #39 and Corning
#3482 filters. A, Kodak Wratten #39 Blue Filter; B, Corning Glass
#3482 Sharp Cut-off Orange Filter.
presence of tumor and the results of therapy with these
methods. Camera adaptations and the availability of laser
light sources may allow the use of these methods in
conjunction with endoscopic techniques.
The development of an instant photographic tech
nique for the detection of HPD (HPD2) in tissue (method
III) is of practical importance to the clinician as well as
to the laboratory scientist. Such a method will allow more
precise localization of neoplastic tissues and provide a
basis for the delivery of photoradiation therapy (PRT) to
specific areas. Method III provides immediate, perma
nent documentation of the local extent of disease.
van der Putten and van Gemert [ 1983a,b] have used
a mathematical modelling theory to investigate the pos
sible detection of subcutaneous tumors after HPD injec
tion. Such studies indicate that it is possible to document
the presence of subcutaneous tumors using this or a
similar technique.
Photographic methods will be useful for monitoring
the dispersion of HPD and related drugs in target tissues
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Effect of Hematoporphyrin Derivative 2 on
Estrogen Receptors in Experimental
Mammary Tumors
Raymond J. Lanzafame, md, David W. Rogers, bs, John O. Nairn, ms,
H. Raul Herrera, md, and J. Raymond Hinshaw, md, d Phil
Department of Surgery, Rochester General Hospital and the University of Rochester School
ofMedicine, Rochester, New York
This study reports the effect of hematoporphyrin derivative 2 (HPD2) on estrogen
receptors (ER) in the animal model used to develop the clinical ER assay. Fifty
200-g female Sprague-Dawley rats were given 20 mg of dimethylbenzanthracene
by gastric intubation. Spontaneous mammary tumors occurred in 35 animals.
Animals were anesthetized and 50% of each tumor was removed when the tumors
were 2 cm in diameter. Animals were then randomized to receive 5 mg/kg (group
A), 10 mg/kg (group B), or 0 mg/kg (group C) HPD2 intravenously 48 hours
after biopsy. The remaining tumor was excised 48 hours post HPD2 injection. All
samples were weighed, placed on ice, and frozen to -70C. ER assay was
performed by batch run. Results (fmol/mg cytosol) were as follows: All animals
(n= 35) pre HPD2 34.2 + 5.4, post HPD2 34.2 5.8; group A: (n=ll) pre
HPD2 33.9 + 7.9, post HPD2 37.1 + 7.8; group B: (n=13) pre HPD2
29.2 3.8, post HPD2 25.5 3.6; group C: (n=ll) pre HPD2 40.3 + 5.2,
post HPD2 41.5 + 7.9. HPD2 does not affect ER in this animal model. Confir
matory studies with human tumor material must be completed.
Key words: cancer, rodents, tumor markers, porphyrins, estrogen receptor analysis, dimethylben
zanthracene, dihematoporphyrin ether
INTRODUCTION
Breast cancer is a common disease in the United
States. Approximately 115,000 new cases are reported
yearly [Cancer Statistics, 1984]. Hematoporphyrin deriv
ative (HPD), when coupled with photodynamic therapy
(PDT), effectively destroys tumor [Dahlman et al, 1983;
Dougherty et al, 1978, 1979, 1981; Kinsey et al, 1983].
Results with HPDPDT in recurrent human breast carci
noma [Dougherty et al, 1979] suggest that it may some
day be a useful adjunct in the treatment of primary breast
cancer. However, it is imperative to determine the effect
of HPD on estrogen receptor (ER) analysis prior to
embarking on prospective human
studies. Such informa
tion is important since ER values are key components in
the planning of postoperative therapies
and since it is
known that factors affecting the viability of
breast tumor
samples may adversely affect ER
analysis and accuracy.
This study was undertaken to
determine the effect of




mammary tumor model was chosen
because it was used
to develop the clinical ER assay. Fifty 200-g
female
Sprague-Dawley rats were given 20 mg of DMBA by
gastric intubation. Spontaneous mammary tumors
oc-
1987 Alan R. Liss, Inc.
curred in 35 animals at 8 to 12 weeks postintubation. All
tumors occurred in the mammary ridge.
The animals were anesthetized with intraperitoneal
pentobarbital and 50% of each tumor was removed when
the tumors had reached 2 cm in diameter. Each sample
was immediately placed on ice, weighed, and then frozen
and stored at 70C. The animals were then randomized
to receive 5 mg/kg (group A), 10 mg/kg (group B), or 0
mg/kg (group C) ofHPD2 (Photofrin II; Photofrin, Inc.,
Raritan, NJ) intravenously 48 hours after the initial bi
opsy. The remainder of the tumor was excised 48 hours
post HPD2 injection. Again, each sample was immedi
ately placed on ice, weighed, and frozen at -70C.
Histologic study of each tumor was performed to verify
that it was mammary in origin.
Estrogen receptor analysis was performed by batch
run radioimmunoassay technique (Rainen ER Assay; New
England Nuclear, Boston, MA). All analyses were per
formed by a reference laboratory (Bio-Science, Inc.,
Great Neck, NY).
Presented at the 6th Annual Meeting of the American Society for
Laser Medicine and Surgery, Boston, Massachusetts, May 24-26,
1986.
Accepted for publication March 9, 1987.
Address reprint requests to Raymond J. Lanzafame, MD, 1425 Port
land Avenue, Rochester, New York 14621.
Effects of HPD2 on Estrogen Receptors 281
RESULTS
All results are reported as femtomoles per milli
gram (fmol/mg) cytosol and are presented in Table I.
The pre HPD2 injection ER values are compared with
the postinjection values for each group. Statistical analy
sis of the results by ANOVA was performed. There was
no difference between the pretreatment ER values for
each group. Similarly, the postinjection ER values were
not different from the pretreatment values. These results
indicate that HPD2 does not alter ER values in this
animal model.
DISCUSSION
Sixty percent of human breast carcinomas are rich
in estrogen receptors [Tourville, 1984]. Approximately
60% of ER-positive patients will respond to hormonal
manipulation therapy, while 90% of ER-negative patients
fail to respond to treatment [Tourville, 1984; Gibson and
Hilf, 1976]. It is therefore important to determine what
effect any potential therapy might have on ER analysis
since accurate ER information plays a key role in the
planning of postoperative therapy in the breast cancer
patient.
Encouraging results have been demonstrated in the
treatment of advanced and recurrent human breast carci
noma [Dougherty et al, 1979]. Such therapy may be
considered for adjunctive or primary treatment in human
breast cancer since HPDPDT is able to destroy tumor
cells locally with minimal adverse effects at distant sites
and little potential of injury to adjacent structures. This
therapy becomes increasingly more attractive in the
growing climate of conservational breast surgery in the
treatment of cancer. HPDPDT may allow the use of
minimal surgical procedures with rates of cure compara
ble or superior to conventional modalities.
The DMBA-mammary tumor model was chosen
for study because it is rich in ER. McGuire and
DeLa-
Garza [1973] demonstrated that these tumors contain an
estradiol binding protein with similar or identical activity
to human mammary carcinoma. This model
served as the
basis for the development of the clinical radioimmunoas
say for ER.
Estrogen receptor levels are affected by sampling
technique, tissue handling and storage, and factors
which
adversely affect cellular viability in the
specimen to be
analyzed [Leight et al, 1984; Meyer et al, 1983; Rosen
thal, 1979; Webster et al, 1978]. Variation was
mini
mized in this study by the sharp excision of each sample,
its immediate placement on ice, and rapid freezing and
storage at -70C. Despite this careful technique, wide
variations in pre- and post-treatment values were noted
in some animals. Similar results have been observed by
TABLE I
Cytosol)























ANOVA analysis is NS for pre- and post-injection values. Differ
ences in ER values between the groups was not significant. P > .05.
HPD2, hematoporphyrin derivative 2.
Hilf and co-workers [Gibson and Hilf, 1976, 1980; Shaife
and Hilf, 1978; Hilf et al, 1983]. Variability in ER values
would be expected since these tumors are spontaneous
and are nonhomogeneous, containing varying amounts of
ER-rich tissue and fibrous stroma. Our results are in
agreement with the average value of 30 fmol/mg cytosol
reported for this tumor model [Gibson and Hilf, 1980].
Our results clearly demonstrate that HPD2 has no
effect on ER analysis in this model. While confirmatory
studies are necessary with human breast tumors, these
results suggest that HPDPDT protocols are possible with
out fear of compromising ER analysis data.
SUMMARY
DMBA mammary tumors were induced in 35 fe
male Sprague-Dawley rats. Animals were randomized
into groups and received 5 mg/kg, 10 mg/kg, or 0 mg/
kg HPD2 intravenously. Tumors were biopsied both be
fore and following HPD2 injection, and ER analysis was
performed. There was no difference in ER activity before
or after HPD2 injection. HPD2 has no effect on ER
activity in this model.
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Effect of CO Laser Excision on Neuroblastoma.
Carter J. McCormack, M.D., John O. Nairn, M.S., David W. Rogers, B.S., Mortiz M.
Ziegler, M.D. , J. Raymond Hinshaw, M.D. , Departments of Surgery,
Children'
s Hospital,
Philadelphia, Pennsylvania, Rochester General Hospital, Rochester, New York.
Neuroblastoma is a common solid tumor in children and continues to have a poor out
come. Surgical excision is the primary treatment but can be limited by invasion
around unresectable structures often leaving residual tumor. The C-1300 murine
neuroblastoma is similar to the human disease and a suitable animal model. We
studied the effect of C0~ laser excision on the growth of residual neuroblastoma.
A partial excision model was developed to simulate the clinical experience . A/J
male mice were innoculated with C-1300 murine neuroblastoma. Seventy five percent
excision of tumor was performed with scalpel and CO* laser (10 Watts) . Residual
tumor growth rates were charted in 21 mice. C0~ laser excision significantly
decreases the growth of residual neuroblastoma (p C05) . Although there were no
CO laser-induced regressions of neuroblastoma , there were two observed cessations
of tumor growth during the study period with CO laser excision. We conclude that
the CO0 laser is a useful modality in the primary surgical treatment of neuro
blastoma.
Lasers Surg. Med. 7(1):206,
1987.
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HELIUM CADMIUM LASER- INDUCED FLUORESCENCE OF
DIHEMATOPOR-"^
PHYRIN ETHER FOR THE ENDOSCOPIC DETECTION OF CANCER.
D.W. Rogers, B.S. . J.R. Blackman, B.S., J.O. Nairn, M.S.,
R.J. Lanzafame, M.D., H.R. Herrera, M.D. , J.R. Hinshaw,
M.D., D.Phil; Department of Surgery, Rochester General
Hospital, Rochester, New York.
Laser-induced fluorescence (LIF) of dihematoporphyrin ether
(DHE) is a sensitive method for the endoscopic detection of
tumors. This study demonstrates helium-cadmium (HeCd) LIF
of DHE in vitro in a biliary model. Detection of LIF was
accomplished by direct visual inspection and both instant
and 35mm photographic methods via an Olympus BF2T10 fiber-
bronchoscope . DHE was placed onto filter paper discs for
testing. Spectral analysis of SOug DHE/ml 95% ETOH was
obtained with a Perkin-Elmer LS-5 scanning fluorimeter .
Relative fluorescence emission intensity at 6 30nm is as
follows: 1.012 (325nm), 0.186 (406nm), 1.673 (442nm),
1.93 (514nm) . A Liconix 4240NB laser (442nm, 40mW) was
coupled to a Laserguide 1.5cm cylindrical diffusor (CD)
or microdiverging lens (MDL) with a 19mm focusing lens and
NRC F915 fiberoptic positioner . Power outputs of these
systems were 1. 32mW/cm and 31.58mW/cm , respectively at
lem from the tip. Direct observation of LIF was possible
with Laserguard Argon Safety Classes (OD15 at 488nm, OD11
at 514. 6nm) with a visual fluorescence threshold at 1.25ug
DHE/ml 95% ETOH for MDL and 0.5ug DHE/ml 95% ETOH for CD.
Photographic detection was accomplished by using a Corning
Glass #3384 sharp cut-off barrier filter on the camera
systems. Instant photographs with the Olympus SCP10 sys
tem (Polaroid 779 film, 120 sec. exposure) detects 2.5ug/ml
DHE with the MDL and 1.25ug/ml DHE with the CD. 35mm
photography using 15 sec. exposure time
and Kodak ER135
(ASA 400) film detects DHE at a level of 1.25ug/ml DHE
with the MDL. Using 1600 ASA film and a 4 sec. exposure,
the system detects 0.5ug/ml DHE with the MDL and a similar
concentration is detectable at an 8 sec. exposure with the
CD. The HeCd laser provides a stable, inexpensive, low
maintenance system for the excitation of DHE. Work is in
progress with these systems to demonstrate
endoscopic
fluorescence of DHE in vivo.
Lasers Surg. Med. 7(1):102, 1987.
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PHOTOGRAPHIC DEMONSTRATION OF PENETRATION OF DIHEMATOPOR
PHYRIN ETHER PREPARATIONS INTO TUMOR SYSTEMS.
R.J. Lanzafame, M.D., D.W. Rogers , B.S., J.O. Nairn, M.S.,
H.R. Herrera, M.D. , J.R. Hinshaw, M.D., D.Phil; Department
of Surgery, Rochester General Hospital , Rochester , New
York. Reduction of systemic toxicity of dihematoporphyrin
ether (DHE) depends on local delivery of drug to its tar
get tissue in sufficient quantities to bind to the target
while minimizing the total body dose. This paper describes
the ability of DHE-admixtures to penetrate and localize in
in-vitro and in-vivo tumor systems. Each system was eval
uated photographically . All studies were performed using
the R3230AC mammary tumor. For the in-vitro studies 24
tumors with an average weight of 2
.2g
were trimmed,
bisected and placed in tissue culture wells containing
Hanks solution. A 5mm hole was punched into the center of
24 tumor halves with a Keyes punch. Each tumor well was
filled with 0.55ml of test solution: 500ug DHE in Azone
Ethanol:H20 (2:93:5) or 5ug DHE in Hanks solution. Tumors
were maintained at constant temperature , removed from the
cuvettes, blotted, bisected and photographed at 1/2, 2, 4,
6,3 or 24 hours. The azone mixture resulted in DHE aggre
gates and tissue fixation with no penetration of DHE.
The DHE/Hanks mixture resulted in 2mm penetration by 24
hours. A second study was performed by immersing bisected
tumors into wells containing 50Oug/DHE/Hanks or DHE .-Azone:
Ethanol:H20 (500ug/ml :2 :48 :50 ) . The DHE/Azone/Ethanol/
H20 mixture resulted in 1.5mm penetration of DHE into tumor
capillaries , crevices 'and tissue defects . An in vivo study
was performed . Test solutions were injected at 4 sites
around tumors'} 1.5cm size. A concentration of 4.5mg/ml
DHE dissolved in 2% Azone-Phosphate Buffered Saline (PBS),
PBS or 10% lipid emulsion were injected (2ml) around the
tumors. Tumors were excised, bisected post-injection and
compared to negative (no DHE) and positive (15mg/kg DHE IV)
controls. Each solution resulted in complete tumor pene
tration and fluorescence similar to the positive controls
at 4 and 18 hours. The lipid emulsion had a greater ten
dency to remain in situ. Further sutdies with lipid-DHE
emulsions are warranted .
Lasers Surg. Med. 7(1):104, 1987.
